

## Extracorporeal shock wave therapy for erectile dysfunction: rethinking study design, implementation, and analysis

Janak Desai<sup>1</sup>, Eric Huyghe<sup>2,3,4</sup>, Gayle D. Maffulli<sup>5</sup>, Carmen Nussbaum-Krammer<sup>6</sup>, Jessica Tittelmeier<sup>6</sup>, Christoph Schmitz<sup>6</sup>

<sup>1</sup> Department of Urology, Samved Hospital, Ahmedabad, India; [drjanakddesai@gmail.com](mailto:drjanakddesai@gmail.com)

<sup>2</sup> Department of Reproductive Medicine, Paule-de-Viguiere Hospital, Toulouse University Hospital, Toulouse, France; [eric.huyghe@yahoo.fr](mailto:eric.huyghe@yahoo.fr)

<sup>3</sup> Department of Urology, Andrology and Renal Transplantation, Ranguel Hospital, Toulouse University Hospital, Toulouse, France

<sup>4</sup> UMR DEFE Inserm 1203, University of Toulouse 3, Toulouse, France

<sup>5</sup> SportsMed UK, London, UK; [g.maffulli7@gmail.com](mailto:g.maffulli7@gmail.com)

<sup>6</sup> Department of Anatomy II, Faculty of Medicine, LMU Munich, 80336 Munich, Germany

### ABSTRACT

**Introduction:** Extracorporeal shock wave therapy (ESWT) for erectile dysfunction (ED) presents a challenging paradox. While numerous clinical studies, systematic reviews, and meta-analyses have been published, indicating a substantial body of evidence supporting the efficacy and safety of ESWT, significant questions remain. Notably, the American Urological Association (AUA) continues to classify ESWT for ED as investigational (Evidence Level: Grade C), suggesting that the true therapeutic effect of ESWT may differ considerably from current estimates. This review aims to critically assess the evidence and propose strategies to address this unresolved discrepancy.

**Data sources:** We systematically searched two electronic databases (PubMed and Ovid/Embase) and published systematic reviews on ESWT for ED and compiled a systematic literature review and meta-analysis based on 87 relevant studies.

**Areas of agreement:** There is clear evidence that ESWT for ED is effective and can therefore be a valuable treatment modality in the management of ED.

**Areas of controversy:** Current assessments of ESWT for ED as investigational by, e.g., the AUA may not stem from a lack of clinical studies, insufficient related basic science, or an inadequate number of systematic reviews and meta-analyses. Instead, the deficits lie in the area of the scientific quality of the clinical studies published to date.

**Growing points:** We hypothesize that this unfortunate situation will only change if the following aspects will be rigorously considered in future clinical studies on ESWT for ED: adequate characterization and reporting of extracorporeal shock waves, appropriate handling of missing data and intercurrent events, and comprehensive classification of ESWT in the overall context of the available treatment options for ED.

**Areas for developing research:** We are convinced that the consistent implementation of these aspects will significantly contribute to establishing ESWT as the first truly regenerative therapy in the management of ED. This overall aim justifies the corresponding efforts, for the benefit of our patients.

### Correspondence

Christoph Schmitz  
Chair of Anatomy II  
Institute of Anatomy  
Faculty of Medicine  
Ludwig-Maximilians University  
Pettenkoferstr. 11  
80336 Munich  
Germany  
Phone: +49-89-2180-72620  
[christoph.schmitz@med.uni-muenchen.de](mailto:christoph.schmitz@med.uni-muenchen.de)

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

## ABSTRACT

**Introduction:** Extracorporeal shock wave therapy (ESWT) for erectile dysfunction (ED) presents a challenging paradox. While numerous clinical studies, systematic reviews, and meta-analyses have been published, indicating a substantial body of evidence supporting the efficacy and safety of ESWT, significant questions remain. Notably, the American Urological Association (AUA) continues to classify ESWT for ED as investigational (Evidence Level: Grade C), suggesting that the true therapeutic effect of ESWT may differ considerably from current estimates. This review aims to critically assess the evidence and propose strategies to address this unresolved discrepancy.

**Data sources:** We systematically searched two electronic databases (PubMed and Ovid/Embase) and published systematic reviews on ESWT for ED and compiled a systematic literature review and meta-analysis based on 87 relevant studies.

**Areas of agreement:** There is clear evidence that ESWT for ED is effective and can therefore be a valuable treatment modality in the management of ED.

**Areas of controversy:** Current assessments of ESWT for ED as investigational by, e.g., the AUA may not stem from a lack of clinical studies, insufficient related basic science, or an inadequate number of systematic reviews and meta-analyses. Instead, the deficits lie in the area of the scientific quality of the clinical studies published to date.

**Growing points:** We hypothesize that this unfortunate situation will only change if the following aspects will be rigorously considered in future clinical studies on ESWT for ED: adequate characterization and reporting of extracorporeal shock waves, appropriate handling of missing data and intercurrent events, and comprehensive classification of ESWT in the overall context of the available treatment options for ED.

**Areas for developing research:** We are convinced that the consistent implementation of these aspects will significantly contribute to establishing ESWT as the first truly regenerative therapy in the management of ED. This overall aim justifies the corresponding efforts, for the benefit of our patients.

**Keywords** acoustic pressure fields, clinical trials, extracorporeal shock wave therapy, ESWT, erectile dysfunction, estimand, intercurrent events, missing data imputation.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

## INTRODUCTION

Erectile dysfunction (ED) is a widespread condition that mainly affects men over 40 years of age and is increasing in prevalence worldwide.<sup>1-3</sup> It is characterized by the constant or repeated inability to achieve and maintain an erection sufficient for satisfactory sexual performance. The pathophysiology of ED is complex and includes various organic, psychogenic, and mixed factors.<sup>3</sup> The etiology of ED is often associated with comorbidities, including cardiovascular disease and diabetes.<sup>2-4</sup> Furthermore, neurological disorders and conditions after radical prostatectomy may play important roles in the development of ED.<sup>2,3</sup> Untreated ED may lead to low self-esteem, strained interpersonal relationships, anxiety and depression.<sup>2,3</sup>

The treatment modalities for ED recommended in guidelines of, e.g., the European Urological Association (EUA) and the American Urological Association (AUA) include Phosphodiesterase-5 inhibitors (PDE5i), inflatable penile prostheses, vacuum erection devices, intracavernosal injections of alprostadil or other drugs, and intraurethral administration of alprostadil.<sup>5-7</sup> However, none of these treatment modalities can be considered a curative and regenerative therapy of ED.

Over the last 15 years extracorporeal shock wave therapy (ESWT) has emerged as an attractive, non-invasive treatment modality in the management of ED.<sup>3,7,8</sup> Originally developed for cracking kidney stones (extracorporeal shock wave lithotripsy),<sup>9</sup> ESWT has been successfully used for over 30 years to manage a variety of pathologies of the musculoskeletal system.<sup>10-12</sup> Numerous molecular and cellular mechanisms of action of extracorporeal shock waves (ESWs) on bone and cartilage tissue, connective tissue as well as muscle and nerve tissue have been identified,<sup>13</sup> making it attractive to use ESWT also in pathologies other than those of the musculoskeletal system. The ability of ESWs to induce functional angiogenesis is of particular relevance in this regard.<sup>13-15</sup>

However, current evaluations of ESWT for ED in the literature and among medical society guidelines come to different conclusions. Sixteen systematic reviews and meta-analyses of clinical studies on ESWT published between 2017 and 2024 (summarized in Table 1) largely indicate that ESWT is an effective intervention for ED.<sup>16-31</sup> Furthermore, the European Association of Urologists recommends (albeit with weak rating) the use of ESWT with/without PDE5i in patients (i) with mild vasculogenic ED, (ii) as an alternative therapy in well-informed patients who do not wish to have or are not suitable for oral vasoactive therapy, and/or (iii) who are vasculogenic ED patients who are poor responders to PDE5i.<sup>32</sup> ESWT for ED is also recommended by the European Society for Sexual Medicine.<sup>5</sup>

In contrast, the most recent guidelines of the AUA on ED designate ESWT for ED as investigational (Conditional Recommendation; Evidence Level: Grade C).<sup>6</sup> Evidence Level Grade C is defined by the AUA as low ("our confidence

in the effect estimate is limited / the true effect may be substantially different from the estimate of the effect") or very low ("we have very little confidence in the effect estimate / the true effect is likely to be substantially different from the estimate of effect").<sup>33</sup>

A comprehensive assessment of the aforementioned systematic reviews and meta-analyses<sup>16-31</sup> indicate that many studies were excluded from further analysis in these reviews, leaving several critical aspects insufficiently addressed. Specifically, three primary aspects were not, or only barely, critically addressed: (i) the characterization of the different types of ESWs applied in ESWT for ED (focused / unfocused / linear / radial ESWs) where energy density values were frequently mentioned without clarification of whether these values represent positive or total energy density, and where in the three-dimensional (3D) acoustic pressure field of an ESW this energy density is reached, (ii) strategies for managing missing data and intercurrent events in clinical studies on ESWT for ED, and (iii) the integration of ESWT within the broader spectrum of available treatments for ED, particularly with respect to optimizing therapy through targeted combination of several treatment modalities.

Based on these observations we performed a systematic review of clinical studies on ESWT for ED that were published until September 27<sup>th</sup>, 2024, with a particular focus on the aforementioned topics and without excluding those studies that were not suitable for a meta-analysis. The conclusion of our systematic assessment of 87 studies extends beyond the conditional recommendation (investigational) of the AUA: we recommend a fundamental re-evaluation in the design, implementation and analysis of clinical studies on ESWT for ED.

## METHODS

A systematic search was conducted on PubMed and Ovid/Embase using the terms "erectile dysfunction shock wave" and "erectile dysfunction shockwave" from the days of inception of these databases until September 27, 2024, according to the 2020 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)<sup>34</sup> guidelines. The strategy of the assessment of the identified reports is summarized in Figure 1. For PubMed these searches retrieved 270 and 199 records, respectively. In Ovid/Embase, both searches led to the proposed subject headings "erectile dysfunction" and "shock wave therapy". Combining these subject headings in a single search with Boolean operator AND yielded 110 records. Thus, the total number of records identified from databases was 579, of which 220 were duplicates that were removed before screening. Furthermore, the 16 meta-analyses listed in Table 1 were searched for studies that were not found in PubMed and Ovid/Embase. After removal of abstracts of presentations at scientific conferences, one additional record remained. Automation tools for marking records as ineligible were not used.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**Table 1** | Conclusions regarding the efficacy of extracorporeal shock wave therapy for erectile dysfunction in systematic reviews and meta-analyses published between 2017 and 2024.

R	NFA	Y-P	Conclusion
16	Hinojosa-Gonzalez	2024	Our network meta-analysis suggests that low-intensity extracorporeal shockwave therapy is an effective intervention for erectile dysfunction, as measured by increases in the IIEF-EF.
17	Vieiralves	2023	The literature presents little scientific evidence but suggests good results with the use of LI-EST for ED.
18	Mason	2023	The examined studies present encouraging results for the use of LI-ESWT to treat diabetic men with ED.
19	Liu	2022	Compared with placebo treatment, LI-ESWT alleviates ED symptoms in patients, particularly those who have mild or moderate ED.
20	Rho	2022	The results of this analysis indicate that LI-ESWT showed a statistically significant effect on early recovery in penile rehabilitation of ED following RP.
21	Yao	2022	The results of this meta-analysis suggest that treatment plans with an energy density of 0.09 mJ/mm <sup>2</sup> and pulses number of 1,500 to 2,000 are more beneficial to IIEF in ED patients. In addition, IIEF improvement was more pronounced in patients with moderate ED after extracorporeal shockwave therapy.
22	Canguven	2021	The present review found that LI-ESWT has a role in ED treatment in laboratory studies, but its role in human clinical trials is still controversial.
23	Kalka	2021	Evidence exists that LI-ESWT generated with an electrohydraulic unit is effective.
24	Ochoa	2021	SW may have a theoretical impact on the vascular etiology of organic ED.
25	Dong	2019	In meta-analysis of seven RCTs with men who received LI-ESWT for ED, there was evidence that the IIEF-EF and EHS experienced improvements following LI-ESWT.
26	Sokolakis	2019	The present meta-analysis provided results showing that LI-ESWT significantly improves erectile function in patients with vasculogenic ED.
27	Campbell	2019	This therapeutic strategy appears to be well tolerated with short-term benefits.
28	Man	2018	These studies suggest that LI-ESWT could significantly improve the IIEF and EHS of patients with ED.
29	Angulo	2017	According to the literature, treatment with LI-ESWT for erectile dysfunction is effective, both in the short and medium term. LI-ESWT has been described as more effective than placebo in the short term.
30	Lu	2017	The number of studies of LI-ESWT for ED have increased dramatically in recent years. Most of these studies presented encouraging results, regardless of variation in LI-ESWT setup parameters or treatment protocols. These studies suggest that LI-ESWT could significantly improve the IIEF and EHS of ED patients.
31	Clavijo	2017	In this meta-analysis of seven randomized controlled trials, treatment of ED with LI-ESWT resulted in a significant increase in IIEF-EF scores.

Abbreviations: R, reference; N-FA, name of the first author; Y-P, year of publication; IIEF, International Index of Erectile Function; IIEF-EF, IIEF - Erectile Domain; ED, erectile dysfunction; RP, radical prostatectomy; SW, shock waves; RCTs, randomized controlled trials; EHS, Erection Hardness Score.

The resulting 360 records were screened, and studies on other pathologies than ED (e.g., Peyronie's disease), reviews, commentaries, editorials, letters to the editor and studies on animal models were excluded (together 268 records). From the 92 reports sought for retrieval (references in Supplementary Data), all but one were downloaded from the E-media library of LMU Munich (Munich, Germany) or obtained through other sources, and were assessed for eligibility. Translation from languages other than English was performed using Google Translate. One case series<sup>35</sup> (n=32 patients; no control group) in Chinese language was not retrieved.

Four of the 91 reports assessed for eligibility were excluded from further analysis. (i) Two publications<sup>36,37</sup> were preliminary reports (named clinical trial updates by the authors) of a randomized controlled trial (RCT)<sup>38</sup> after enrollment of approximately 25%<sup>36</sup> or 50%<sup>37</sup> of the patients into the RCT. (ii) One publication<sup>39</sup> was a national, multi-institutional, retrospective progress report about the use of four different ESWT devices in treatment of ED. However, the partially incorrect descriptions of the ESWT devices in this report<sup>39</sup> raised doubts about the scientific integrity of the entire publication. Specifically, the BTL-6000 SWT device (BTL, Prague, Czech Republic) was described as electropneumatic


generator with focused-wave morphology but actually generates radial ESWs (rESWs), whereas the 250 device (Shenzen Huikang Medical Apparatus Co., Shenzhen, China) was described as electromagnetic generator with radial-wave morphology but actually generates focused ESWs (fESWs). (iii) In one study<sup>40</sup> only approximately two thirds of the patients suffered from ED, without separate reporting of the results of the ED patients.

The remaining 87 reports were included in the systematic review. 40 of them were reports of case series without control groups, 15 were reports of cohort studies with one or more, non-randomized control groups and 32 were reports of RCTs.

Table 2 summarizes the variables that were extracted from the 87 identified reports. For case series, 38 variables were extracted, and for cohort studies and RCTs with one / two / three control groups 45 / 50 / 55 variables.

Statistical analysis (calculation of mean, standard deviation, median and range of the investigated variables as well as Wilcoxon matched-pairs signed rank test for effect estimation) were calculated using GraphPad Prism (Version 10.3.1 for Windows; GraphPad Software, Boston, MA USA). Furthermore, a meta-analysis was performed using the software Comprehensive Meta-Analysis (Version 4; Biostat, Inc., Englewood, NJ, USA). P values smaller than 0.05 were

considered statistically significant.



**Figure 1** | Systematic review flow chart of the literature search regarding extracorporeal shock wave therapy for erectile dysfunction, performed according to the PRISMA guidelines<sup>34</sup> on September 27, 2024.

**Table 2** | Variables extracted from the 87 reports on extracorporeal shock wave therapy (ESWT) for erectile dysfunction (ED) identified in the systematic literature search outlined in Figure 1.

Name	Variable
<b>A - General information</b>	
V1	Name of the first author
V2	Year of publication
V3	The country (or countries) in which the clinical trial was performed were specified (country name(s) / not specified)
V4	The type of investigated erectile dysfunction was specified (vasculogenic / organic / post-radical prostatectomy / diverse / not specified)
V5	The patients were non-responders to PDE5i (yes / no / both / not specified)
V6	The blood testosterone level of all patients enrolled in the trial was normal (yes / no / not specified)
V7	Testosterone replacement therapy was performed in case of testosterone deficiency (yes / no / not applicable)
V8	The IIEF-EF score was determined to enable comparison of treatment outcome with other studies on ESWT for ED, including the first description in the literature (yes / no)
V9	The type of clinical trial was specified (case series / cohort study / RCT)
V10	Control groups were specified (not applicable / 1 / 2 / 3 / etc.)
V11	It was specified whether the data were prospectively or retrospectively collected (prospective / retrospective / not specified)
V12	The time post-baseline or post-treatment [weeks] at which the primary endpoint was determined was specified. (Note: in this systematic review sometimes data from a different time point were used for analysis in order to keep the times post-treatment as homogeneous as possible.)

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Name	Variable
V13	Additional follow-up times [weeks or months] were reported (values / not applicable)
<b>B – ESWT device used</b>	
V14	The exact name of the used device was specified (name / not specified)
V15	The manufacturer's name, country, and city of the headquarter were specified (data / not specified)
V16	The type of generated ESWs was specified (focused (F) / unfocused (U) / linear (L) / radial (R) / not specified)
V17	The technology of ESW generation was specified (electrohydraulic (EH) / electromagnetic (EM) / piezoelectric (PE) / electromagnetic-ballistic (EMB) / pneumatic-ballistic (PB) / not specified)
<b>C – (Main) ESWT group</b>	
V18	The number of patients in the (main) ESWT group was specified (number / not specified)
V19	The number of patients in the (main) ESWT group lost to follow-up was specified (number / not specified)
V20	The age of the patients [years] in the (main) ESWT group was specified (minimum / median / mean / standard deviation / maximum / interquartile distance / not specified)
V21	The duration of erectile dysfunction before baseline [months] of the patients in the (main) ESWT group was specified (minimum / median / mean / standard deviation / maximum / interquartile distance / not specified)
V22	The number of treatment sessions was specified (number / not specified)
V23	The time sequence of the treatment sessions was specified (weeks and number of sessions per week / not specified)
V24	The number of ESWs per treatment session was specified (number of treatment regions distributed over the penis times number of ESWs per treatment region / not specified)
V25	The type of the reported energy density of the ESWs was specified (ED <sup>+</sup> / ED <sup>total</sup> / not specified whether ED <sup>+</sup> or ED <sup>total</sup> )
V26	The energy density of the ESWs [mJ/mm <sup>2</sup> ] was specified (value / not specified).
V27	Alternatively, there was another description of the energy settings of ESWs (KV / mJ / Bar)
V28	The three-dimensional (3D) acoustic pressure field of the applied ESWs (i.e., for the device settings used in the clinical trial) was analyzed, including determination of the 3D regional distribution of the peak positive pressure, peak negative pressure, and the resulting energy density (yes / no)
V29	Alternatively, the report referred to a publication in which the 3D acoustic pressure field of the applied ESWs (i.e., for the device settings used in the clinical trial) was analyzed as described in V28 (yes / no)
V30	The frequency of the applied ESWs [Hz] was specified (value / not specified)
V31	Additional treatment(s) next to ESWT were specified (additional treatment(s) / no additional treatment(s))
<b>D – First control group (if applicable)</b>	
V32	Data corresponding to V18
V33	Data corresponding to V19
V34	Data corresponding to V20
V35	Data corresponding to V21
V36	The treatment(s) of the patients in the first control group were specified (treatment(s) / not specified)
<b>E – Second control group (if applicable)</b>	
V37	Data corresponding to V18
V38	Data corresponding to V19
V39	Data corresponding to V20
V40	Data corresponding to V21
V41	Data corresponding to V36
<b>F – Third control group (if applicable)</b>	
V42	Data corresponding to V18
V43	Data corresponding to V19
V44	Data corresponding to V20
V45	Data corresponding to V21
V46	Data corresponding to V36
<b>G – Statistical analysis</b>	
V47	An Intent-to-Treat analysis was performed (yes / no)
V48	There were missing data due to patients lost to follow-up (yes / no)
V49	Missing data imputation was performed (yes / no / not applicable as no patient was lost to follow-up)
V50	The method(s) used for missing data imputation were specified (method(s) / not applicable)
V51	An estimand strategy for handling intercurrent events was developed (yes / no)
V52	The reported data are suitable for calculating an average mean ± SD of mean IIEF-EF data reported in different clinical trials at baseline and at follow-up (i.e., mean IIEF-EF values at baseline and at follow-up must be reported) (data)
V53	The data were suitable for a meta-analysis (i.e., mean, SD and number of patients in the ESWT group and the main control group were available at baseline and at follow-up, and use or non-use of ESWT was the only difference between the groups (sham treatment was considered non-use of ESWT)) (yes / no / not applicable for case series)
<b>H – Therapeutic outcome</b>	
V54	ESWT resulted in a statistically significant improvement of erectile dysfunction compared to baseline (yes / no / not applicable)
V55	ESWT resulted in a statistically significant improvement of erectile dysfunction compared to sham or control treatment (not applicable for case series; A, ESWT+, C-, ESWT > C; B, ESWT+, C+, ESWT > C; C, ESWT+, C+, ESWT = C; D, ESWT-, C-, ESWT = C; E, ESWT-, C+, ESWT < C)

## RESULTS

The 87 eligible studies exhibited considerable heterogeneity in the investigated variables (all extracted values are provided in Supplementary Data).

### *Type of ED*

In 34 of 87 (39%) studies, vasculogenic ED was investigated, in 18 (21%) studies organic ED, in 12 (14%) studies diverse kinds of ED, in 10 (11%) studies ED post-radical prostatectomy, and in one (1%) study each ED in the presence of Peyronie's disease, priapism-induced ED, ED on the basis of chronic pelvic pain syndrome, veno-occlusive ED based on hypogonadotropic hypogonadism, post pelvic fractures associated with urethral injury, and multifactorial ED in kidney transplant recipients. In 7 (8%) studies the type of investigated ED was not specified.

### *Collection of data*

In 62 of 87 (71%) studies, the data were prospectively collected, and in 15 (17%) studies retrospectively. In 10 (11%) studies it was not specified whether the data were prospectively or retrospectively collected.

### *Response to PDE5i*

In 20 of 87 (23%) studies, the patients were non-responders to PDE5i, whereas in 64 (74%) studies this was not the case. In 3 (3%) studies both responders and non-responders to PDE5i were included.

### *Blood testosterone levels*

In 34 of 87 (39%) studies, the blood testosterone level of all enrolled patients was normal. In 3 (3%) studies this was not the case and, thus, testosterone replacement therapy was performed in case of testosterone deficiency. However, in 50 (57%) studies the blood testosterone level of the enrolled patients was not specified.

### *IIEF-EF score*

In 37 of 87 (43%) studies, the International Index of Erectile Function - Erectile Domain (IIEF-EF) score<sup>41</sup> was determined to enable comparison of treatment outcome with other studies on ESWT for ED, including the first description in the literature.<sup>42</sup> In 50 (57%) studies this was not the case.

### *Number of patients*

The number of patients in the (main) ESWT group varied between 5 and 710 (mean, 55; standard deviation (SD), 87; median, 35), and the number of patients in the first (main) control group varied between 10 and 484 (mean, 45; SD, 68, median, 34). In six studies a second control group was investigated in which the number of patients varied between 24 and 178 (mean, 72; SD, 68, median, 34.5). Furthermore, in one study a third control group with 25 patients was investigated.

### *Age of the patients*

The average age of the patients could not be calculated, as several studies reported only median data. The average of the 64 of 87 (74%) reported mean ages of patients in the (main) ESWT group was 53.3 years  $\pm$  8.6 years (mean  $\pm$  SD), and the

average of the 22 (25%) reported median ages of patients in the (main) ESWT group was 58.8 years  $\pm$  3.8 years. Furthermore, in 37 (43%) studies the range of the age of the patients in the (main) ESWT group was specified; the lower limit varied between 19 years and 55 years (mean, 36 years; SD, 11 years; median, 33 years) and the upper limit varied between 36 years and 84 years (mean, 71 years; SD, 9 years; median, 72 years). In one study the age of the patients was not specified.

### *Duration of ED before baseline*

The average duration of ED before baseline of the patients in the (main) ESWT group could neither be calculated, as several studies reported only median data. However, the following information could be extracted from the provided data: (i) in 28 of 77 (36%) studies addressing ED other than post-prostatectomy the mean duration of ED before baseline was specified, with values varying between 5.5 months and 118 months (mean, 43.8 months; SD, 27.7 months; median, 34.6 months); (ii) in 16 of 77 (21%) studies the median duration of ED before baseline was specified; these values varied between 12 months and 68 months (mean, 47.1 months; SD, 15.8 months; median, 46 months); (iii) in 19 of 77 (25%) studies a lower limit of the duration of ED before baseline was reported ( $3 \times > 3$  months,  $14 \times > 6$  months and  $2 \times > 12$  months), and in 1 of 77 (1%) studies an upper limit ( $< 6$  months); (iv) in 23 of 77 (30%) studies the range of the duration of ED before baseline was specified; the lower limit varied between 3 months and 36 months (mean, 10.8 months; SD, 7.2 months; median, 9 months) and the upper limit varied between 12 months and 240 months (mean, 116 months; SD, 82 months; median, 84 months); and (v) in 13 of 77 (17%) studies the duration of ED before baseline was not specified.

### *ESWT devices used*


The electrohydraulic (EH), electromagnetic (EM), piezoelectric (PE) and ballistic principles for generating ESWs are schematically shown in Figure 2 (taken from<sup>11</sup> which was published under the Creative Commons CC-BY-NC license).

In 22 of 87 (25%) studies the focused part of the EM device, Duolith SD1 (fESWs; Storz Medical, Tägerwil, Switzerland) was used, in 18 (21%) studies the EH device, Omnispec ED1000 (fESWs; Medispec, Yehud, Israel), in 10 (12%) studies the EM device, Renova (linear ESWs (IESWs); Direx, Petah Tikva, Israel), in 9 (10%) studies the PE device, Piezowave 2 with FBL10x5G2 handpiece (IESWs; Richard Wolf, Knittlingen, Germany); in 7 (8%) studies the EM device, Aries 2 (fESWs; Dornier MedTech, Weßling, Germany) and in 2 (2%) studies the EH device, UroGold 100 (fESWs; MTS, Konstanz, Germany) Furthermore, in one (1%) study each the following devices were used: BTL-6000 SWT (pneumatic-ballistic (P-B); rESWs; BTL); enPulse Pro (electromagnetic-ballistic (EM-B); rESWs, Zimmer, Neu-Ulm, Germany); ESWO-I 80 mm (EM; fESWs; Shenzhen Hyde Medical Equipment Co, Shenzhen, China); GentlePro (EM-B; rESWs; Zimmer); HB-ESWT-01 (not specified; fESWs; Zhanjiang Haibin Medical Equipment Co,

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Guangdong, China); Intellect Focus Shockwave Therapy SKU (EM; fESWs; Chattanooga, Chattanooga, TN, USA); LGT-2510B (P-B; rESWs; Guangzhou Longest Medical Technology Co, Guangzhou, China); Masterpuls MP50 (P-B; rESWs, Storz Medical); MoreNova (EM; IESWs; Direx); MT 2000H (EM; fESWs; Urontech, Hwaseong, Korea);

OrthoGold 100 (EH; fESWs; MTS, Konstanz, Germany); Piezowave 2 with FB10G6 handpiece (PE; fESWs; Richard Wolf); Swiss DolorClast with EvoBlue Handpiece (P-B; rESWs; Electro Medical Systems) and WellWave (PE; fESWs; Richard Wolf). In 5 (6%) studies the used device was not specified.



**Figure 2** | Schematic representation of the mode of operation of focused (A-C) and radial (D) extracorporeal shock wave generators (taken from<sup>11</sup> which was published under the Creative Commons CC-BY-NC license). (A) Electrohydraulic principle (focused extracorporeal shock waves (fESWs)): a high voltage discharges rapidly across two electrode tips (spark-gap) (1) that are positioned in water. The spark-gap serves as the first focal point (1). The heat generated by this process vaporizes the surrounding water. This generates a gas bubble centered on the first focal point, with the gas bubble being filled with water vapor and plasma. The result of the very rapid expansion of this bubble is a sonic pulse, and the subsequent implosion of this bubble causes a reverse pulse, manifesting a shock wave. By means of reflectors of certain shape (2), this shock wave can be converted into a convergent/focused acoustic pressure wave/shock wave with a point of highest pressure at the second focal point (3). (B) Electromagnetic principle (fESWs): a strong, variable magnetic field is generated by passing a high electric current through a coil (4). This causes a high current in an opposed metal membrane (5), which causes an adjacent membrane (6) with surrounding liquid to be forced rapidly away. Because the adjacent membrane is highly conductive, it is forced away so rapidly that the compression of the surrounding liquid generates a shock wave within the liquid. By means of an acoustic lens (7) of certain shape, this shock wave can be converted into a convergent/focused acoustic pressure wave/shock wave with a point of highest pressure at a focal point (8). (C) Piezoelectric principle (fESWs): a large number of piezocrystals (9) are mounted in a bowl-shaped device (10); the number of piezocrystals can vary from a few to several thousands (typically between 1,000 and 2,000). When applying a rapid electrical discharge, the piezocrystals react with a deformation (contraction and expansion), which is known as the piezoelectric effect. This induces an acoustic pressure pulse in the surrounding water that can steep into a shock wave. Because of the design of the bowl-shaped device an acoustic pressure wave/shock wave can emerge with a point of highest pressure at a focal point (11). (D) Ballistic principle (rESWT): compressed air (pneumatic principle; 12) or a magnetic field (not shown) is used to fire a projectile (13) within a guiding tube (14) that strikes a metal applicator (15) placed on the patient's skin. The projectile generates stress waves in the applicator that transmit pressure waves into tissue (16). Linearly formed extracorporeal shock waves can be generated by using different designs of the components of extracorporeal shock wave generators shown in this figure. For example, in linear piezoelectric devices many subassemblies as the one shown in (C) can be arranged serially.

It should be mentioned that in one study<sup>43</sup> in which the Duolith SD1 (Storz Medical) was used a linearly formed transducer head was described, without providing further details. It is unknown whether this linearly formed transducer head generated IESWs similar to the Renova (Direx), MoreNova (Direx) and the Piezowave 2 with FBL10x5G2 handpiece (Richard Wolf), or whether this was a regular fESW transducer head with a standoff with an elongated recess/trough. In the other 21 studies in which the

Duolith SD1 (Storz Medical) was used, a linearly formed transducer was not mentioned. As in the same study<sup>43</sup> the patients were also treated with a curved transducer head (which was probably the regular handpiece of the Duolith SD1 (Storz Medical) that generates fESWs), this study was considered focused ESWT in this systematic review.

#### **Types of ESWs applied**

In 56 of 87 (65%) studies focused ESWs were applied, in

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

20 (23%) studies linear ESWs, in 6 (7%) studies radial ESWs and in 1 (1%) study unfocused ESWs. In 4 (5%) studies the type of ESWs was not specified or could not be determined by the description of the used device.

### Treatment protocols

The treatment protocols were analyzed both cumulatively and separately for studies in which fESWs, lESWs and rESWs were applied (details of the separate analysis are summarized

fESWs / lESWs / rESWs were applied.

in Table 3). The most commonly used treatment protocols were Week 1 (W1) to W3 and W7-W9 with one treatment session per week (Protocol A; 16 of 87 (18%) studies), W1-W4 with one treatment session per week (Protocol B; 12 (14%) studies), and W1-W6 with one treatment session per week (Protocol C; also 12 (14%) studies). Various other treatment protocols were used. Of note, Protocols A / B / C were the most commonly used treatment protocol among those studies in which

**Table 3** | Details of the treatment protocols of extracorporeal shock wave therapy for erectile dysfunction used in the 87 clinical trials identified in this systematic review, stratified by the type of the applied extracorporeal shock waves. Data are provided as mean  $\pm$  standard deviation (median; range). The numbers in brackets indicate the numbers of reports that provided the corresponding raw data.

	fESWs	lESWs	rESWs
TS	9.0 $\pm$ 3.3 (9; 4 – 18) [56]	5.6 $\pm$ 2.2 (4.5; 4 – 10) [20]	6.7 $\pm$ 1.0 (6; 6 – 8) [6]
ESWs/TS	2773 $\pm$ 1556 (3000; 1500 – 10,000) [55]	3746 $\pm$ 1758 (3800; 600 – 6600) [20]	5000 $\pm$ 2828 (4500; 2000 – 10,000) [6]
$\Sigma$ ESWs	24,558 $\pm$ 16,690 (18,000; 8000 – 90,000) [55]	18,980 $\pm$ 9633 (18,600; 3600 – 39,600) [20]	33,000 $\pm$ 17,697 (27,000; 12,000 – 60,000) [6]
EnD [mJ/mm <sup>2</sup> ]	0.14 $\pm$ 0.07 (0.09; 0.05 – 0.25) [47]	0.11 $\pm$ 0.03 (0.09; 0.09 – 0.16) [17]	0.09 $\pm$ 0.0 (0.09; 0.09 – 0.09) [2]
$\Sigma$ EnD [J/mm <sup>2</sup> ]	3.25 $\pm$ 2.46 (1.8; 0.81 – 9) [47]	2.19 $\pm$ 1.44 (1.8; 0.54 – 6.34) [17]	1.89 $\pm$ 1.15 (1.9; 1.1 – 2.7) [2]
F [Hz]	3.8 $\pm$ 1.8 (3.7; 1.7 – 8) [44]	5.3 $\pm$ 1.8 (5; 2 – 8) [9]	13.7 $\pm$ 2.9 (12; 12 – 17) [3]
$\Sigma$ TT [min]	119 $\pm$ 66 (116; 33 – 400) [44]	58 $\pm$ 45 (48; 20 – 167) [9]	41 $\pm$ 23 (33; 24 – 67) [3]
P	W1-W3 and W7-W9 (1x per week) [13]	W1-W4 (1x per week) [9]	W1-W6 (1x per week) [3]

Abbreviations: fESWs, focused extracorporeal shock waves; lESWs, linear extracorporeal shock waves; rESWs, radial extracorporeal shock waves; TS, number of therapy sessions; ESWs/TS, number of extracorporeal shock waves per therapy session;  $\Sigma$ ESWs, total number of applied extracorporeal shock waves (TS x ESWs/TS); EnD, energy density;  $\Sigma$ EnD, cumulated energy density applied ( $\Sigma$ ESWs x EnD); F, frequency at which the ESWs were applied;  $\Sigma$ TT, total treatment time ( $\Sigma$ ESWs / F); P, the most commonly used treatment protocol; W, week.

### Details of the treatment protocols

The number of treatment sessions varied between 4 and 14 (mean, 8.3; SD, 3.3; median, 6; data from 87 studies).

The number of ESWs applied per treatment session varied between 600 and 10,000 (mean, 3022; SD, 1743; median, 3000; data from 86 studies as not in all studies all relevant information was provided).

The total number of applied ESWs varied between 3600 and 90,000 (mean, 23,120; SD, 14,684; median, 18,000; data from 86 studies).

The energy density of the applied ESWs varied between 0.05 Millijoule (mJ)/mm<sup>2</sup> and 0.25 mJ/mm<sup>2</sup> (mean, 0.13 mJ/mm<sup>2</sup>; SD, 0.06 mJ/mm<sup>2</sup>; median, 0.09 mJ/mm<sup>2</sup>; data from 71 studies). Obviously incorrect information about the energy density of the applied ESWs (0.009 mJ/mm<sup>2</sup> as well as 20 mJ/mm<sup>2</sup>, 15 mJ/mm<sup>2</sup> and 12 mJ/mm<sup>2</sup>)<sup>44-46</sup> were not considered in these calculations. The same applied to other descriptions of the energy settings of ESWs (including KiloVolt (KV), Millijoule (mJ) and Bar)<sup>47-51</sup> from which without further information no direct conclusions can be drawn about the energy density of the applied ESWs.

The cumulated energy density applied over all treatment sessions varied between 0.54 J/mm<sup>2</sup> and 9 J/mm<sup>2</sup> (mean, 2.83 J/mm<sup>2</sup>; SD, 2.15 J/mm<sup>2</sup>; median, 1.8 J/mm<sup>2</sup>; data from 71

studies).

The frequency of the applied ESWs varied between 1.66 Hz and 17 Hz (mean, 4.3 Hz; SD, 2.7 Hz; median, 4 Hz; data from 58 studies).

From these values the total treatment time was calculated (total number of applied ESWs divided by the frequency at which the ESWs were applied), that varied between 20 min and 500 min (mean, 111 min; SD, 84 min; median, 100 min; data from 60 studies).

Of note, none of the 87 studies specified whether the reported energy density of the ESWs represented the positive or total energy density. Furthermore, no study analyzed the 3D acoustic pressure field of the applied ESWs (i.e., for the device settings used in the study), including determination of the 3D regional distribution of the peak positive pressure, peak negative pressure, and the resulting energy density. Furthermore, none of the studies referenced any publication that provided an analysis of the 3D acoustic pressure field for the ESW device settings used.

### Combination treatments

In 27 of 87 (31%) studies, ESWT was combined with other treatments. These other treatments were PDE5i oral (daily or on demand; 19 studies) and PDE5i oral + L arginine

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

supplement (2 studies), as well as application of ESWTs to the pelvic floor, pelvic floor training, transcranial magnetic stimulation, use of a vacuum erectile device, injection of platelet-rich-plasma and subcutaneous injection of recombinant chorionic gonadotropin plus oral intake of Epimedium Breviconum (1 study each). In 60 (69%) studies ESWT was not combined with other treatments.

### Intent-to-Treat analysis

In 51 of 87 (59%) studies, an Intent-to-Treat (ITT) analysis<sup>52-54</sup> was performed, whereas in 36 (41%) studies this was not the case. Furthermore, in 38 (44%) studies at least one patient was lost to follow-up in any of the investigated groups, with group-specific lost to follow-up rates varying between 2.3% and 100% (mean, 19.7%; SD, 16.8%; median, 16.7%). However, in only 2 of the 38 (5%) studies with missing data, missing data imputation<sup>55,56</sup> was performed (using the Baseline Observation Carried Forward Method).

### Estimand strategy for handling intercurrent events

In only 1 of 87 (1%) studies, an estimand strategy for handling intercurrent events<sup>57-59</sup> was developed.

### Treatment outcome


Among the 77 studies that did not address ED post-prostatectomy, 71 (92%) studies reported a statistically significant improvement in ED from baseline to follow-up. Furthermore, 33 of these 77 (43%) studies reported mean IIEF-EF values at baseline and at follow-up. The mean IIEF-EF values at baseline varied between 7 and 21.2 (mean, 13.7; SD, 3.4; median, 14) and the mean IIEF-EF values at follow-up varied between 12.3 and 25.8 (mean, 19.5; SD, 3.6; median, 20). Statistical analysis using the Wilcoxon matched-pairs signed rank test demonstrated a significant ( $p < 0.001$ ) difference in the mean IIEF-EF values at baseline and at follow-up. The mean follow-up time in these 33 studies varied between 7 and 30 weeks (mean, 18.1 weeks; SD, 7.1 weeks; median, 24 weeks).

In 20 of the 47 (43%) cohort studies and RCTs, ESWT was statistically significantly superior to sham/control treatment. Furthermore, in 5 (11%) of these studies ESWT and sham/control treatment significantly improved ED, but ESWT was not significantly superior to sham/control treatment. In only 2 (4%) of these studies neither ESWT nor sham/control treatment were effective, and in none of these studies sham/control treatment was significantly superior to ESWT. For the remaining 20 cohort studies and RCTs the corresponding analysis could not be performed based on the published data.

### Meta-analysis

19 of the 47 (40%) cohort studies and RCTs were suitable for a meta-analysis (i.e., mean and SD of the primary endpoint (e.g., the IIEF-EF score) as well as the number of patients in the (main) ESWT group and the main control group were reported at baseline and at follow-up, and use or non-use of ESWT was the only difference between the groups (sham

treatment was considered non-use of ESWT)). The details of the meta-analysis are summarized in Figure 3 and Table 4. For the pooled analysis the standard difference in means was 1.53 (variance; 0.06; lower limit, 1.05; upper limit, 2.00; Z-value, 6.26;  $p < 0.001$ ).



**Figure 3** | Results of the meta-analysis of 19 cohort studies and randomized controlled trials on extracorporeal shock wave therapy for erectile dysfunction performed in this systematic review.

### Safety

In none of the 87 studies severe adverse events were reported.

### DISCUSSION

The results of this systematic review can be summarized and interpreted as follows: (i) there is clear evidence that ESWT for ED is effective and safe, and can therefore be a valuable treatment modality in the management of ED; (ii) the AUA is correct in its assessment that the true effect of ESWT for ED may be substantially different from the current estimate of the effect; (iii) without a fundamental shift in the planning, implementation and analysis of clinical studies on ESWT in ED, the assessment by the AUA is unlikely to change, and (iv) future studies on ESWT for ED should include adequate characterization and reporting of extracorporeal shock waves, appropriate handling of missing data and intercurrent events, and comprehensive classification of ESWT in the overall context of the available treatment options for ED.

In the following paragraphs each of these aspects is addressed in detail.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**Table 4** | Details of the meta-analysis of 19 cohort studies and RCTs on extracorporeal shock wave therapy for erectile dysfunction performed in this systematic review.

Ref	Study	T	SD-M	SE	V	LL	UL	Z	P
51	Trishch et al. (2024)	CS	2,384	0,317	0,101	1,762	3,005	7,515	<0,001
60	Karakose et al. (2021)	CS	2,813	0,347	0,121	2,132	3,493	8,099	<0,001
61	Verze et al. (2020)	CS	1,137	0,173	0,03	0,799	1,476	6,591	<0,001
	Pooled (all CSs)		2,082	0,564	0,318	0,976	3,187	3,692	<0,001
62	Kalyvianakis et al. (2024)	RCT	1,547	0,334	0,112	0,892	2,203	4,63	<0,001
63	Kennady et al. (2023)	RCT	0,884	0,359	0,129	0,18	1,588	2,46	0,014
64	Kalyvianakis et al. (2022)	RCT	1,737	0,281	0,079	1,188	2,287	6,193	<0,001
65	Motil et al. (2022)	RCT	0,315	0,318	0,101	-0,308	0,939	0,99	0,322
66	Ong (2022)	RCT	0,927	0,295	0,087	0,349	1,506	3,141	0,002
47	Sand.-Salinas et al. (2022)	RCT	0,25	0,224	0,05	-0,19	0,69	1,114	0,265
67	Ladegaard et al. (2021)	RCT	0,749	0,336	0,113	0,091	1,408	2,23	0,026
68	Shendy et al. (2021)	RCT	1,463	0,347	0,121	0,782	2,144	4,212	<0,001
46	Kim et al. (2020)	RCT	2,433	0,271	0,073	1,903	2,964	8,987	<0,001
69	Sramkova et al. (2019)	RCT	6,565	0,653	0,426	5,286	7,844	10,06	<0,001
70	Yamaçake et al. (2019)	RCT	0,877	0,468	0,219	-0,041	1,794	1,872	0,061
71	Fojecki et al. (2017)	RCT	0,461	0,181	0,033	0,107	0,815	2,554	0,011
72	Kalyvianakis et al. (2017)	RCT	1,224	0,335	0,112	0,568	1,88	3,655	<0,001
73	Srini et al. (2015)	RCT	3,339	0,277	0,077	2,796	3,882	12,047	<0,001
74	Yee et al. (2014)	RCT	0,366	0,241	0,058	-0,107	0,838	1,516	0,129
75	Vardi et al. (2012)	RCT	0,749	0,271	0,074	0,218	1,281	2,762	0,006
	Pooled (all RCTs)		1,424	0,278	0,007	0,879	1,969	5,120	<0,001
	Pooled (all studies)		1,526	0,244	0,059	1,048	2,004	6,259	<0,001

Abbreviations: Ref, reference; T, type of study; CS, cohort study; RCT, randomized controlled trial; SD-M, standard difference in means; SE, standard error; V, variance; LL, lower limit; UL, upper limit; Z, Z-value; P, p-value.

### ***Adequate characterization and reporting of extracorporeal shock waves***

Figure 4A was redrawn from an illustration in a recent review on the basic physics of shock waves for ED (<sup>76</sup>; Fig. 2 therein). The curve shown in this figure was described by the authors of<sup>76</sup> as an idealized pressure vs time plot of a shock wave at one specific point along its trajectory. However, it is important to note that none of the patients suffering from ED in the 87 studies identified in our systematic review were treated with ESWs exhibiting the energy signature shown in Figure 4A. To illustrate this, Figure 4B (taken from<sup>77</sup> with permission<sup>78</sup>) shows a typical averaged pressure vs time plot (averaged from 25 ESWs) at the focus point (explained below) at the maximum output setting of the Duolith SD1 (Storz Medical) that was used in 22 of the 87 studies identified in our systematic review. Compared to the pressure vs time plot in Figure 4A the corresponding plot in Figure 4B shows (i) a substantially lower peak positive pressure ( $p^+$ ) (approximately 43 Megapascal (MPa) vs. 100 MPa), (ii) a steep fall in positive pressure after  $p^+$  with a steepness similar to the steepness of the rise in positive pressure before reaching  $p^+$ , resulting in a much more symmetric curve around  $p^+$  than shown in Figure 4A, and (iii) a much longer phase of negative pressure (approximately 2.3  $\mu$ s vs. approximately 150 ns). The energy density (also outlined below) of the ESWs represented in Figure 4B was determined as 0.23 mJ/mm<sup>2</sup> by the authors of<sup>77</sup>, whereas the nominal setting of the energy density of the Duolith SD1 (Storz Medical) was 0.55 mJ/mm<sup>2</sup> during these


measurements (c.f. Table 1 in<sup>77</sup>). In line with this finding the authors of<sup>77</sup> stated that their results compared qualitatively, but not quantitatively with manufacturer specifications.<sup>77</sup> Moreover, the energy density of the ESWs utilized in ESWT for ED was lower, averaging 0.09 mJ/mm<sup>2</sup> across the majority of the 87 studies identified in our systematic review. This implies that  $p^+$  of the ESWs used in ESWT for ED with the Duolith SD1 (Storz Medical) is lower than shown in Figure 4B. According to<sup>77</sup>, ESWs generated by the Duolith SD1 (Storz Medical) with energy density of 0.12 mJ/mm<sup>2</sup> have a peak positive pressure of 17.5 MPa (Table 1 in<sup>77</sup>), which is much less than the 100 MPa shown in Figure 4A.

Of note, the same study<sup>77</sup> found that (i) shock formation did not occur for any machine settings of the Duolith SD1 (Storz Medical), and (ii) predictions from simulations suggested that a true shock wave (i.e., a shock wave in a strict physical meaning) could be obtained in water if the initial pressure output of the device were doubled.<sup>77</sup> Accordingly, the ESWs generated by the Duolith SD1 (Storz Medical) are focused pressure waves rather than focused true shock waves. This is important because (at least in the context of using the Duolith SD1 (Storz Medical)) there is no scientific justification for distinguishing between focused shock waves and radial pressure waves in ESWT for ED (as done in, e.g.,<sup>47,76</sup>), despite the fact that focused ESWs and radial ESWs have different energy signatures.<sup>11,79-81</sup> Importantly, the question of whether an acoustic wave is a shock wave or a pressure wave is only decided by the part with positive pressure, but not by the part

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

with negative pressure. The findings in<sup>77</sup> raise the question of whether all ESWT treatments of ED are actually performed with focused pressure waves rather than with focused true shock waves. The information provided in the corresponding review articles<sup>76,82</sup> is not suitable to answer this question. In reality, the matter is even more complicated: even if an ESWT device would be used in ESWT for ED that could generate focused true shock waves, and this device would be operated

such that it would actually generate focused true shock waves, this would not imply that the entire target tissue would be treated with focused true shock waves. This is due to the fact that the 3D acoustic pressure fields generated by ESWT devices are not homogeneous with respect to the maximum pressure, energy density and other characteristics of the ESWs.



**Figure 4** | Representative pressure vs time plots and shadow imaging of extracorporeal shock waves for illustration purposes (Part 1). Panel B was taken from<sup>77</sup> with permission<sup>78</sup>; Panels C, D were taken from<sup>80</sup> which was published under the Creative Commons CC BY 2.0 license; and Panels E-J were taken from<sup>86</sup> which was published under the Creative Commons CC BY license. Details are in the main text.

To illustrate this, Figure 4C, D shows a two-dimensional (2D) representation of the 3D, rotationally symmetric, acoustic pressure field generated by an ESWT device that has not been used in the management of ED (PiezoClast; Electro Medical Systems, Nyon, Switzerland). These pictures (taken from<sup>80</sup> which was published under the Creative Commons CC BY 2.0 license) were generated using shadow imaging which requires a powerful light source and a high-speed camera (c.f.<sup>83</sup>). Positive pressure in water results in disturbances that can refract light rays, so they can cast shadows (c.f. Figure 4C). The same applies to cavitation bubbles that occur during the phase of negative pressure of ESWs (Figure 4D).<sup>83,84</sup> In general, cavitation bubbles occur when the pressure in a liquid quickly drops below the vapor pressure.<sup>85</sup> When these cavitation bubbles collapse at the end of the phase of negative pressure of an ESW, a small, secondary shock wave is generated that is a true shock wave in a strict physical meaning. The merging of many of these secondary shock waves, triggered by the almost simultaneous collapse of many cavitation bubbles, can then lead to larger secondary shock waves that propagate radially (as shown in Figure 4D). The elliptical field of cavitation bubbles in Figure 4D already indicates the absence of a homogeneous acoustic pressure field above the applicator of the ESWT device used.

Figure 4E-G (modified from<sup>86</sup> which was published under the Creative Commons CC BY license) shows graphical representations of the applicator of the same ESWT device that was used for shadow imaging in Figure 4C, D (PiezoClast; Electro Medical Systems). Position 1 (indicated by a black point) at 4.5 cm above the applicator represents the spot in Figure 4C where the wave front formed the shock wave focus. This point is also named the focus point. Figure 4H shows the pressure vs time plot of the ESWs measured at this focus point (Figure 4H-J was modified from<sup>86</sup> which was published under the Creative Commons CC BY license). The pressure vs time plot shown in Figure 4H has a peak positive pressure ( $p^+$ ) of approximately +110 MPa (exceeding the threshold of +100 MPa indicated in Figure 4A) and a peak negative pressure ( $p^-$ ) of approximately -20 MPa; both values exceed the corresponding values in Figure 4B. The energy density of the corresponding ESWs was determined as 0.4 mJ/mm<sup>2</sup> in<sup>86</sup>. Furthermore, the pressure vs time plot shown in Figure 4H fulfills the requirements set out in<sup>87</sup> of a focused true shock wave. Figure 4I shows the pressure vs time plot of the same ESWs measured at Position 2 in Figure 4F, which was 9.5 mm above the focus point in the 3D acoustic pressure field. One can see that the absolute values of  $p^+$  and  $p^-$  were substantially lower at Position 2 ( $p^+ = +8.7$  MPa;  $p^- = -7.5$  MPa) than at the focus point ( $p^+ \sim +110$  MPa;  $p^- \sim -20$  MPa). Most importantly, the pressure vs time plot measured at Position 2 was not simply a scaled-down version of the pressure vs time plot

measured at the focus point but showed a different steepness of the rise in positive pressure before reaching  $p^+$ . More generally speaking, unlike the situation at the focus point (c.f. Figure 4H) the pressure vs time plot measured at Position 2 (Figure 4I) did not fulfill the requirements set out in<sup>87</sup> of a focused true shock wave.

Figure 4J shows the pressure vs time plot of the same ESWs measured at Position 3 in Figure 4G, which was 9.5 mm above and 6 mm left to the focus point in the 3D acoustic pressure field. At this position  $p^+$  did not even reach +5 MPa, and the pressure vs time plot measured at Position 3 was neither a scaled-down version of the pressure vs time plot measured at the focus point nor measured at Position 2. Of note, the ratio of the absolute values of  $p^+$  and  $p^-$  was approximately 5.5 (110 MPa/20 MPa) at the focus point, 1.16 (8.7 MPa/7.5 MPa) at Position 2 and 0.91 (4.3 MPa/4.8 MPa) at Position 3.


These measurements demonstrate different acoustic pressure conditions (and, thus, different energy densities) within the 3D acoustic pressure field of an ESW. One characteristic of this 3D acoustic pressure field is the -6 dB (or -3 dB) focus, which is the 3D region around the focus point at which the local  $p^+$  is at least 50% (or at least 70.8%) of  $p^+$  at the focus point.<sup>79</sup> Another characteristic is the 5 MPa focus, which is the 3D region around the focus point at which the local  $p^+$  is at least 5 MPa, regardless of  $p^+$  at the focus point.<sup>79</sup> For the ESWs whose pressure vs time plot at the focus point is shown in Figure 4H, the 5 MPa focus is indicated as gray ellipsoids in Figure 4E-G. Position 2 was inside the 5 MPa focus whereas Position 3 was not.

The energy density of an ESW is defined as

$$\text{Energy density} = \frac{1}{Z} \int_a^b p(t)^2 dt$$

with  $Z$  the impedance of sound in water ( $1.5 \times 10^6$  kg/m<sup>2</sup>s),  $p(t)$  the pressure as a function of time and the integration limits  $a$  and  $b$ . According to IEC-61846<sup>88</sup> there are two types of integration limits. The positive temporal integration limits are defined as the times between which the positive pressure first exceeds 10% of  $p^+$  ( $a^+$  in Figure 5A,B) and the first time it reduces below 10% of  $p^+$  ( $b^+$  in Figure 5A,B)<sup>88</sup> (Figure 5A-D was modified from<sup>86</sup> which was published under the Creative Commons CC BY license). Furthermore, the total temporal integration limits are defined as the times between which the absolute value of the pressure pulse waveform first exceeds 10% of  $p^+$  ( $a^{\text{total}}$  in Figure 5C,D) and the last time it reduces below 10% of  $p^+$  ( $b^{\text{total}}$  in Figure 5C,D).<sup>88</sup> To simplify matters, the hatched areas under the pressure vs time plots in Figure 5A,B represent the positive energy density, and the hatched areas under the pressure vs time plots in Figure 5C,D the total energy density.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



**Figure 5** | Representative pressure vs time plots of extracorporeal shock waves for illustration purposes (Part 2). The curves in (A,C) are the same as in Figure 3H, and the curves in (B,D) are the same as in Figure 3I. Panels A-D were taken from<sup>86</sup> which was published under the Creative Commons CC BY license. Details are in the main text.


Accordingly, the energy density within the 3D acoustic pressure field of an ESW exhibits substantial regional variation. Publications on ESWT for ED typically report the energy density at the focus point. However, none of the 87 studies on ESWT for ED identified in our systematic review stated whether the reported energy density values were the positive or the total energy density. It is important to understand that without this information, none of these 87 studies on ESWT for ED can be independently reproduced.

At first glance one might be inclined to simply assume that the total energy density is a certain multiple of the positive energy density. However, due to complex nonlinear wave physics, ESWs generated by certain ESWT devices may exhibit markedly different energy signatures. For example, Figure 6 shows 2D representations of the positive pressure, negative pressure and energy density of fESWs generated by the Duolith SD1 (Storz Medical) operated at highest settings and with its short standoff (15 mm) obtained by modeling (the panels were taken and modified from<sup>77</sup> with permission<sup>78</sup>, and were squeezed / expanded to scale in X and Y to match the drawing of the -3 dB focus zone of the corresponding ESWs in the same publication<sup>77</sup>, which is shown in Figure 6A). One can see that the spatial distribution of positive pressure (Figure 6B) formed an ellipsoid with highest pressure at the position of the focus point (white arrow in Figure 6B), whereas the spatial distribution of negative pressure (Figure 6C) showed the highest absolute value (gray arrow in Figure 6C) at a position that was approximately 18 mm closer to the applicator than the focus point (white arrow in Figure 6C). As a result,

the spatial distribution of the total energy density was also shifted towards the applicator, and the maximum total energy density (gray arrow in Figure 6D) was not found at the position of the focus point (white arrow in Figure 6D). As mentioned above, the spatial distributions of the positive pressure, negative pressure and energy density shown in Figure 6 do not represent the situation in ESWT for ED using the Duolith SD1 (Storz Medical), as this device is not operated at highest settings in ESWT for ED. To our knowledge comprehensive information corresponding to the one provided in Figure 6B-D has not been published for any other ESWT device used in ESWT for ED.

What implications do these findings have for cells in the target tissue? Cells exposed to ESWs may react differently to the shear stress induced by the positive pressure, as well as to the formation and collapse of cavitation bubbles caused by the negative pressure.<sup>77,83,84</sup> To our knowledge, only three studies addressed the potential impact of cavitation (and, thus, the negative pressure of ESWs) on cells in vitro and biological tissue under experimental conditions.<sup>89-91</sup> Specifically, human fetal foreskin fibroblasts in vitro,<sup>89</sup> *C. elegans* worms<sup>90</sup> and explanted frog sciatic nerves<sup>91</sup> were exposed to ESWs either in water / saline or in polyvinyl alcohol (PVA), a high viscosity solution with low cavitation activity during ESW exposure, an acoustic impedance that is nearly identical to that of water, and relatively low ESW attenuation.<sup>92</sup> In all of these experiments a substantial contribution of cavitation to the effects of ESWs on cells and biological tissue was demonstrated.<sup>89-91</sup>

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



**Figure 6** | Two-dimensional (2D) representations of the spatial distribution of the positive pressure, negative pressure, and energy density of ESWs generated by the Duolith SD1 (Storz Medical) operated at highest settings and with its short standoff obtained by modeling. Panels A-D were taken and modified from Figures 1 and 11 in<sup>77</sup> with permission<sup>78</sup>. Details are in the main text.

Considering the small size of cells (with diameters between 10 and 50  $\mu m$ ) relative to the size of ESWs (Figure 4C), it seems implausible that cells can discern whether they are hit by a focused ESW or a radial ESW. However, cells may react differently to various energy signatures of ESWs, including differences in  $p^+$  and  $p^-$ , duration of exposure to positive and negative pressure, energy density, and the contribution of positive and negative pressure to the total energy density. Accordingly, cells in the target tissue may react very differently to exposure to ESWs, depending on their position within the 3D acoustic pressure field of the applied ESWs.

The specification of respectively KV values (as in<sup>48</sup>), mJ values (as in<sup>49,51</sup>) or bar values (as in<sup>47,50</sup>) does not allow to

draw conclusions about the characteristics of ESWs without additional information. This is due to the fact that these values describe the input energy in different types of ESWT devices to generate ESWs rather than the energy density of the resulting ESWs. Specifically, KV (Kilovolt) describes the current that is rapidly discharged across two electrode tips (spark-gap) to vaporize the surrounding water in electrohydraulic ESWT devices (c.f. Figure 2A).<sup>11</sup> For the EH device, Evotron (HealthTronics, Marietta, GA, USA; not used in any of the 87 studies identified in our systematic review) it was shown that different energy settings (and, thus, different KV values) resulted in ESWs with very similar energy density.<sup>84</sup> Furthermore, mJ describes the energy that is used to

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

electromagnetically accelerate the bullet in certain radial ESWT devices (c.f. Figure 2D), including the enPulse pro device (Zimmer, Neu-Ulm, Germany; used in<sup>49</sup> for treating ED). It would be necessary to determine the energy density of the resulting rESWs as done for pneumatically generated rESWs.<sup>83,93</sup> Moreover, the term Bar describes the air pressure that is used to accelerate the bullet in pneumatic, radial ESWT devices (c.f. Figure 2D). For the Swiss DolorClast with the EvoBlue handpiece and 15 mm applicator (Electro Medical Systems; used in<sup>87</sup> for treating ED) a good correlation between the air pressure and the energy density of the resulting rESWs was demonstrated, with a loss of approximately 20% in the positive energy density between rESWs generated at 1 Hz and those generated at 25 Hz.<sup>93</sup> In contrast, the radial ESWs generated by the MasterPuls 200 Ultra with Falcon handpiece and 15 mm applicator (Storz Medical; not used in any of the 87 studies identified in our systematic review) showed a loss of up to 90% in the positive energy density between rESWs generated at 1 Hz and those generated at 21 Hz.<sup>93</sup> Furthermore, at 1 Hz frequency the rESWs generated by the MasterPuls 200 Ultra / Falcon handpiece / 15 mm applicator (Storz Medical) had consistently lower positive energy densities than the rESWs generated by the Swiss DolorClast / EvoBlue handpiece / 15 mm applicator (Electro Medical Systems).<sup>93</sup> To our knowledge the corresponding characteristics of the rESWs generated by the BTL-6000 SWT (BTL; used in<sup>50</sup> for treating ED) and the MasterPuls 50 (Storz Medical; used in<sup>47</sup> for treating ED) have not been published.

Finally, it should be noted that several studies on ESWT for ED either lacked information on the energy density and other characteristic of the ESWs used,<sup>94-98</sup> or included information that was evidently inaccurate.<sup>44,46</sup> Specifically, in<sup>44</sup> it was stated that patients received 6 treatment sessions, with 3 x 1000 focused ESWs (Duolith SD1; Storz Medical) with energy densities of 12 mJ/mm<sup>2</sup>, 15 mJ/mm<sup>2</sup> and 20 mJ/mm<sup>2</sup>. Furthermore, in<sup>46</sup> it was stated that patients received 12 treatment sessions, with 3 x 1000 focused ESWs (MT 2000H device; Urontech Korea, Hwaseong, Korea) with energy densities of 12 mJ/mm<sup>2</sup>, 15 mJ/mm<sup>2</sup> and 20 mJ/mm<sup>2</sup>. However, these values neither represent the energy density of single fESWs nor the cumulated energy density of all fESWs applied to a certain penile region or during a treatment session. Moreover, in<sup>45</sup> it was stated that patients received 12 treatment sessions, with 5 x 300 fESWs (Aries 2; Dornier MedTech, Weßling, Germany) with energy density of 0.009 mJ/mm<sup>2</sup>. This is only 10% of the 0.09 mJ/mm<sup>2</sup> used in the majority of the 87 studies identified in our systematic review and most likely a typographical error. In summary, the characteristics of the 3D acoustic pressure fields to which penile tissue is exposed during ESWT for ED remain largely unknown. In particular, different ESWT devices that are operated at the same energy density at the focus point (e.g., 0.09 mJ/mm<sup>2</sup>) may expose penile tissue to very different 3D acoustic pressure fields. There is no doubt that the precise characterization of these 3D acoustic pressure fields is a mandatory prerequisite for optimizing treatment protocols to improve the effectiveness of ESWT for ED. We hypothesize,

over time, this improved assessment of ESWT for ED may contribute to a more favorable assessment by organizations such as the AUA. It is clear that manufacturers of ESWT devices play a critical role in the characterization of the 3D acoustic pressure fields of the ESWs generated by their devices under exactly the conditions used in ESWT for ED.

#### ***Appropriate handling of missing data and intercurrent events***

Consider a hypothetical clinical study investigating the efficacy of three novel drugs for treating ED. In this study, researchers randomly assigned n=150 patients suffering from vasculogenic ED to three groups (Groups A, B and C; n=50 patients each). Each group received one of three drugs (Drugs A, B and C). The patients' IIEF-EF score was determined at baseline and at six months post-treatment initiation (M6). At baseline, all groups had an average IIEF-EF score of  $8 \pm 2$  (mean  $\pm$  SD), indicating that the patients suffered from severe ED. At M6, n=30 / 45 / 40 patients in Groups A / B / C could be analyzed and had an average IIEF-EF score of  $26 \pm 3$  /  $12 \pm 4$  /  $20 \pm 4$ . Statistical analysis of the results with analysis of variance (ANOVA) followed by Bonferroni post tests for pairwise comparison demonstrated statistically significant differences in the mean IIEF-EF score at M6, with Group A > Group C > Group B. Based on these results, the investigators concluded that Drug A is superior to Drugs B and C, while Drug B is superior to Drug C in treating ED. Consequently, they recommended Drug A as preferred option in the management of ED.

Later the following was revealed. In Group A, n=20 patients suddenly and unexpectedly died between baseline and M6, and all deaths were probably or possibly related to study treatment. In Group B, n=5 patients moved to another country shortly after the start of the treatment and were lost to follow-up. In Group C, the patients quickly realized that Drug C was not effective and may be a placebo treatment. As a result, n=10 patients in Group C dropped out of the study because of lack of efficacy, and n=30 patients in Group C used concomitant medication which was not disclosed to the study investigators. Considering this additional information, Drug A must not be used in the management of ED, Drug B was not effective, and the real impact of Drug C on improvement of ED could not be determined.

This admittedly extreme example of a hypothetical clinical study and its results demonstrates the absolute necessity and clinical relevance of critical missing and non-missing data imputation in clinical studies. In this example, missing data imputation would have been necessary in all groups. However, the reasons for missing data were completely different among the groups, which requires different strategies and methods for missing data imputation. Furthermore, in Group C the data obtained at M6 of those patients who used undisclosed concomitant medication were biased and were to be replaced, which requires non-missing data imputation.

More broadly, clinical study results for ED should be subjected to an ITT analysis, with estimand strategies for handling intercurrent events developed and clearly

It is made available under a [CC-BY 4.0 International license](#).

documented in the study protocol. A detailed discussion of these analyzes and strategies lies beyond the scope of this review, as they are thoroughly addressed elsewhere.<sup>52-59</sup>

In brief, ITT analysis includes all patients in a clinical study, regardless of whether the patients completed the study.<sup>52-54</sup> All leading methods for assessing the methodological quality of RCTs include a critical check of whether an ITT analysis was performed.<sup>99-104</sup> Missing data can be Missing Completely at Random (which means that there is no relationship between the missingness of the data and any values, observed or missing), Missing at Random (which implies a systematic relationship between the propensity of missing values and the observed data, but not the missing data) or Missing Not at Random (which implies a relationship between the propensity of a value to be missing and its values), respectively.<sup>55</sup> Various methods are available to handle missing data in results of clinical studies, including Baseline Observation Carried Forward, Last Observation Carried Forward, the Expectation Maximization Algorithm, Treatment based Monte Carlo Markov Chain multiple imputation, among others.<sup>55,56</sup>

The four components of an estimand are Population (i.e., the target population for the research question), Variables (i.e., the endpoints that were obtained from all patients), Intercurrent Events (i.e., all events that occurred after treatment initiation and either precluded the observation of a variable, or affected its interpretation) and Population-Level Summary (i.e., the variables on which the comparison between treatments was based).<sup>57-59</sup> Furthermore, there are five strategies how to handle intercurrent events: Treatment Policy strategy (in this case it is irrelevant whether an intercurrent event has occurred or not; the data will be collected and analyzed regardless), Composite Strategy (in this case the occurrence of the intercurrent event is incorporated into the endpoint), Hypothetical Strategy (in this case the aim of the clinical study is to estimate the treatment effect in the hypothetical situation where the intercurrent event did not occur), Principal Stratum Strategy (in this case the aim is to estimate the treatment effect within the stratum of patients for whom the intercurrent event did not occur) and Wile on Treatment Strategy (in this case measurements of the endpoint are considered up until the time of the intercurrent event).<sup>57,58,105</sup>

A detailed assessment of the 87 studies on ESWT for ED included in our systematic review, specifically regarding ITT analysis and development of estimand strategies with focus on handling intercurrent events, revealed concerning findings. No study included a detailed strategy for handling intercurrent events as outlined above, and the term Estimand was absent from all of these studies. In one study<sup>44</sup> rudimentary intercurrent events handling was performed by excluding data of patients from the analysis who reported de novo use of erectogenic aids at the first follow-up. Furthermore, in 38 (44%) studies at least one patient was lost to follow-up in any of the investigated groups, but in only two of these studies<sup>106,107</sup> missing data imputation was performed (note that the absence of missing data should not be interpreted as a justification for not developing a detailed strategy for handling

intercurrent events, as the latter also includes potential non-missing data imputation). Considering that at least 15 studies identified in our systematic review described retrospective analysis of existing data (in 10 studies it was not described whether the data were prospectively or retrospectively collected) the relative number of prospective studies with missing data was even higher. Meta-analyses may be particularly sensitive to lack of missing data imputation. In the case of the meta-analysis performed in this review, in 8 of 19 (42%) studies data were missing that were not imputed.

In the following section, three studies identified in our systematic review are shortly described as examples, in which missing data imputation was either not or incorrectly performed. (i) In<sup>108</sup>  $n=710$  patients suffering from ED were retrospectively analyzed after five weekly ESWT sessions. The last follow-up examination took place one month after the last treatment (i.e., nine weeks after baseline; W9). At this time 298 of 710 (42%) patients were lost and only 412 patients were examined at W9.<sup>108</sup> Thus, the results reported at W9 represented the results of only 58% of the patients who were included in the study but were compared with the results obtained from all 710 patients after the last treatment.<sup>108</sup> No attempt was made to impute the missing data as a prerequisite for performing an ITT analysis. (ii) In<sup>109</sup>  $n=115$  patients were non-randomly assigned after radical prostatectomy to treatment with PDE5i ( $n=59$ ) or ESWT + PDE5i ( $n=56$ ). The last follow-up examination took place six months after surgery (M6). At this time 15 of 56 (27%) patients in the ESWT + PDE5i group and 20 of 59 (34%) patients in the PDE5i group were lost to follow-up. Again, no attempt was made to impute the missing data as a prerequisite for performing an ITT analysis. (iii) In<sup>106</sup>  $n=66$  patients suffering from ED were randomly assigned to ESWT ( $n=44$ ) or placebo treatment (PT;  $n=22$ ). Follow-up examinations were performed at three months after baseline (M3), M6 and M12. However, only patients who were considered treatment responders were examined at M6 and M12. The number of examined patients in the ESWT / PT groups were 42 / 22 at M3, 26 / 4 at M6 and 19 / 0 at M12. Accordingly, only 19 of 44 (43%) of the patients in the ESWT group and 0 of 22 (0%) of the patients in the PT group were considered treatment responders and examined at M12. Missing data (i.e., data of patients who were not considered treatment responders and, thus, not examined at M3, M6 and/or M12) were imputed using the Baseline Observation Carried Forward method. Due to this approach the results of the PT group at M12 were exactly the same as the data at baseline, although no patient in the PT group was examined at M12.

In summary, the almost complete lack of developing strategies for handling intercurrent events as well as missing or incorrect ITT analysis in approximately one third of the 87 studies on ESWT for ED identified in our systematic review should be considered a major obstacle to determining the actual effect of this treatment modality in the management of ED. The current assessment of ESWT for ED by organizations such as the AUA (investigational; Evidence Level Grade C) may be directly related to this issue. While managing missing

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

data and intercurrent events in clinical study analyses can be complex, the literature referenced in this review<sup>52-59</sup> offers a valuable introduction to the relevant concepts and methods. Furthermore, missing data imputation can be accessed through statistical software such as R<sup>110</sup> that is also available for free.<sup>111</sup>

It should be mentioned that long-term monitoring of the efficacy of ESWT for ED in comparison with other treatment modalities (including sham/placebo ESWT) could greatly benefit from analysis using the Kaplan-Meier estimator.<sup>112</sup> Briefly, in oncology research the Kaplan-Meier estimator is widely used to measure the fraction of patients living for a certain amount of time after treatment. This can easily be modified to measure the fraction of patients exceeding, e.g., a certain IIEF-EF score for a certain amount of time after treatment, similar to the use of the Kaplan-Meier estimator in determining long-term outcome after treatment of knee osteoarthritis.<sup>113-115</sup>

### *Classification of ESWT in the overall context of the available treatment options for ED*

The search for optimal combinations of ESWT with other treatment modalities in the management of ED is currently still in its infancy. In a recent, comprehensive review<sup>3</sup> the following treatment modalities for ED were outlined in detail; the numbers in parentheses indicate the absolute and relative numbers of studies identified in our systematic review in which ESWT was combined with these treatment modalities: PDE5i (21; 24%), physiotherapeutic exercises (1; 1%), L-arginine supplementation (2; 2%) and vacuum pump rehabilitation (1, 1%). No study combined ESWT with intracavernosal self-injection therapy, medicated urethral system for erection; lifestyle modification, L-citrulline supplementation, ginseng, Vitamin D, curcumin, or psychotherapy/counseling, respectively.

It is beyond the scope of this review to develop a comprehensive strategy for combining ESWT with other treatment modalities in the management of ED. In particular, this would require a thorough search for potential matches between the pathophysiology of certain subtypes of ED (e.g., vasculogenic, post-prostatectomy) with the molecular and cellular mechanisms of action of ESWs and the aforementioned other treatment modalities on connective, muscle, and nerve tissue. However, it must be considered that the mere description of a mechanism of action for ESWT in a study does not necessarily imply that this mechanism is relevant to the observed clinical effects.<sup>13</sup>

Clinical studies on ESWT for ED that do not account for patients' blood testosterone levels should be considered outdated and should not be included in future evaluations of this treatment modality. Furthermore, ESWT for ED should always be combined with pelvic floor muscle training, which can provide additional benefits by targeting specific areas relevant to erectile dysfunction.<sup>3</sup> Given that ESWT is highly effective in treating functional/ultrastructural muscle injuries<sup>116</sup> it is reasonable to hypothesize that, in addition to applying ESWs on penile tissue, targeting the pelvic floor

muscles with ESWs (as performed in<sup>47</sup>) may further improve the efficacy of ESWT for ED.

In summary, the possibilities for clinical researchers to combine ESWT with other treatment modalities in the management of ED are virtually limitless. The available literature does not indicate any possible mutual blockages of the mechanisms of action of ESWT and the other treatment modalities mentioned, as is the case, e.g., with the combination of ESWT and certain muscle relaxants in the treatment of chronic, nonspecific low back pain<sup>117</sup> or the combination of ESWT and diclofenac (a nonsteroidal anti-inflammatory drug) in the treatment of structural muscle injuries.<sup>118</sup> However, the consistent implementation of the other two aspects of ESWT for ED discussed here (adequate characterization of ESWs, appropriate handling of missing data and intercurrent events) seems to us at present to be more important than considering possible combination therapies.

### **LIMITATIONS**

The main limitation of this systematic review is that the impact of the substantial heterogeneity of the investigated variables (type of ED, response to PDE5i, IIEF-EF scores at baseline, patient's age, duration of ED before baseline, type of applied ESWs, details of the treatment protocols) on the treatment outcome in the 87 assessed studies was not further discussed. It is correct that (i) younger patients may respond differently to ESWT for ED than older patients, (ii) ED post-prostatectomy and vasculogenic ED have a different pathophysiology that may require different treatment protocols, and (iii) patients suffering from ED for 20 years may experience different outcome of ESWT than patients suffering from ED for a few months, etc. Conversely, reported differences in treatment outcome may be substantially biased by profound differences in the 3D acoustic pressure fields of the applied ESWs (even if the specified energy density was the same) and inappropriate handling of missing data and intercurrent events. As in case of combination therapies these issues should be addressed first before analyzing the impact of differences in types of ED, subgroups of patients and treatment protocols on the outcome of ESWT for ED.

### **CONCLUSION**

Current assessments of ESWT for ED as investigational (by, e.g., the AUA; Evidence Level: Grade C) may not stem from a lack of clinical studies, insufficient related basic science, or an inadequate number of systematic reviews and meta-analyses. Instead, the deficits lie in the area of the scientific quality of the clinical studies published to date, as detailed in this systematic review. We hypothesize that this unfortunate situation will only change if the following aspects will be rigorously considered in future clinical studies on ESWT for ED: adequate characterization of ESWs, appropriate handling of missing data and intercurrent events, and comprehensive classification of ESWT in the overall context of the available treatment options for ED. Conversely, we are convinced that the consistent implementation of these aspects will significantly contribute to establishing ESWT as

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

the first truly regenerative therapy in the management of ED. This overall aim justifies the corresponding efforts, for the benefit of our patients.

### Author contributions

Janak Desai (Conceptualization, Writing – review & editing), Eric Huyghe (Conceptualization, Writing – review & editing), Gayle Maffulli (Conceptualization, Writing – review & editing), Carmen Nussbaum-Krammer (Conceptualization, Formal Analysis, Writing – review & editing), Jessica Tittelmeier (Conceptualization, Formal Analysis, Writing – review & editing), Christoph Schmitz (Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Software, Visualization, Writing – original draft).

### Supplementary material

Supplementary material is available at the end of this preprint.

### REFERENCES

1. Muneer A, Kalsi J, Nazareth I, Arya M. Erectile dysfunction. *BMJ* 2014;348:g129. <https://doi.org/10.1136/bmj.g129>.
2. Leslie SW, Sooriyamoorthy T. Erectile dysfunction. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing, 2024.
3. Beecken WD, Kersting M, Kunert W et al. Thinking about pathomechanisms and current treatment of erectile dysfunction – "The Stanley Beamish problem." Review, recommendations, and proposals. *Sex Med Rev* 2021;9:445-463. <https://doi.org/10.1016/j.sxmr.2020.11.004>.
4. Orimoloye OA, Feldman DI, Blaha MJ. Erectile dysfunction links to cardiovascular disease-defining the clinical value. *Trends Cardiovasc Med* 2019;29(8):458-465. <https://doi.org/10.1016/j.tcm.2019.01.002>.
5. Low intensity shock wave therapy in sexual medicine – clinical recommendations from the European Society of Sexual Medicine (ESSM). <https://www.essm.org/low-intensity-shock-wave-therapy-in-sexual-medicine-clinical-recommendations-from-the-european-society-of-sexual-medicine-essm/> (10 December 2024, date last accessed).
6. American Urological Association (AUA) guidelines on erectile dysfunction (ED). <https://emedicine.medscape.com/article/444220-guidelines> (10 December 2024, date last accessed).
7. Nguyen V, McGovern AM, Rojanasart S et al. Patient out-of-pocket costs for guideline-recommended treatments for erectile dysfunction: a medicare cost modeling analysis. *Int J Impot Res* 2024 Jun 26: online ahead of print. <https://doi.org/10.1038/s41443-024-00903-9>.
8. Weinberger JM, Shahinyan GK, Yang SC, Shahinyan RH, Mills JN, Eleswarapu SV. Shock wave therapy for erectile dysfunction: marketing and practice trends in major metropolitan areas in the United States. *Urol Pract* 2022;9:212-219. <https://doi.org/10.1097/UPJ.000000000000299>.
9. Rassweiler JJ, Knoll T, Köhrmann KU, McAteer JA, Lingeman JE, Cleveland RO, Bailey MR, Chaussy C. Shock wave technology and application: an update. *Eur Urol* 2011;59(5):784-96. <https://doi.org/10.1016/j.eururo.2011.02.033>.
10. Speed C. A systematic review of shockwave therapies in soft tissue conditions: Focusing on the evidence. *Br. J. Sports Med* 2014;48:1538–1542. <https://doi.org/10.1136/bjsports-2012-091961>.
11. Schmitz C, Császár NB, Milz S et al. Efficacy and safety of extracorporeal shock wave therapy for orthopedic conditions: a systematic review on studies listed in the PEDro database. *Br Med Bull* 2015;116:115-38. <https://doi.org/10.1093/bmb/ldv047>.
12. Reilly JM, Bluman E, Tenforde AS. Effect of shockwave treatment for management of upper and lower extremity musculoskeletal conditions: a narrative review. *PM R* 2018;10:1385-1403. <https://doi.org/10.1016/j.pmrj.2018.05.007>.
13. Wuerfel T, Schmitz C, Jokinen LLJ. The effects of the exposure of musculoskeletal tissue to extracorporeal shock waves. *Biomedicines* 2022;10:1084. <https://doi.org/10.3390/biomedicines10051084>.
14. Contaldo C, Högger DC, Khorrami Borozadi M, Stotz M, Platz U, Forster N, Lindenblatt N, Giovanoli P. Radial pressure waves mediate apoptosis and functional angiogenesis during wound repair in ApoE deficient mice. *Microvasc Res* 2012;84(1):24-33. <https://doi.org/10.1016/j.mvr.2012.03.006>.
15. Kisch T, Wuerfel W, Forstmeier V, Liodaki E, Stang FH, Knobloch K, Mailaender P, Kraemer R. Repetitive shock wave therapy improves muscular microcirculation. *J Surg Res* 2016;201(2):440-445. <https://doi.org/10.1016/j.jss.2015.11.049>.
16. Hinojosa-Gonzalez DE, Talamas Mendoza A, Torres-Martinez M et al. Indirect assessment of low-intensity shockwave therapy's energy density and pulse frequency for erectile dysfunction: a systematic review, bayesian network meta-analysis and meta-regression. *Int J Impot Res* 2024 May 23: online ahead of print. <https://doi.org/10.1038/s41443-024-00910-w>.
17. Vieirals RR, Schuh MF, Favorito LA. Low-intensity extracorporeal shockwave therapy in the treatment of erectile dysfunction – a narrative review. *Int Braz J Urol* 2023;49:428-440. <https://doi.org/10.1590/S1677-5538.IBJU.2023.9904>.
18. Mason MM, Pai RK, Masterson JM, Lokeshwar SD, Chu KY, Ramasamy R. Low-intensity extracorporeal shockwave therapy for diabetic men with erectile dysfunction: A systematic scoping

### Disclosures and Competing Interests

JD serves as speaker for the Swiss Urology Academy, owned by Electro Medical Systems S.A. (Nyon, Switzerland). Electro Medical Systems is the manufacturer and distributor of the Swiss DolorClast and PiezoClast devices mentioned in this article. EH is President of the French College of Sexology and Sexual Medicine and is in charge of the Andrology and Sexual Medicine Committee of the French Association of Urology. GM is a Director for Harley Street Shockwave and Rejuvenation Clinic Limited and is the Coordinator for the British Shockwave and Rejuvenation Association. CS has served as Consultant for Electro Medical Systems. However, Electro Medical Systems had no role in study design, data collection, and analysis, interpretation of the data, and no role in the decision to publish and write this manuscript. No other potential conflicts of interest relevant to this article were reported.

### Data availability

The data underlying this article are available in the article and in its online supplementary material.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

- review. *Andrology* 2023;11:270-281. <https://doi.org/10.1111/andr.13197>.
19. Liu S, Pu J, Li X, Li R, Wang Y, Dong Z. Effects of Low-intensity extracorporeal shockwave therapy on erectile dysfunction: a systematic review and meta-analysis. *J Coll Physicians Surg Pak* 2022;32:1181-1186. <https://doi.org/10.29271/jcpsp.2022.09.1181>.
  20. Rho BY, Kim SH, Ryu JK, Kang DH, Kim JW, Chung DY. Efficacy of low-intensity extracorporeal shock wave treatment in erectile dysfunction following radical prostatectomy: a systematic review and meta-analysis. *J Clin Med* 2022;11:2775. <https://doi.org/10.3390/jcm11102775>.
  21. Yao H, Wang X, Liu H et al. Systematic review and meta-analysis of 16 randomized controlled trials of clinical outcomes of low-intensity extracorporeal shock wave therapy in treating erectile dysfunction. *Am J Mens Health* 2022;16:15579883221087532. <https://doi.org/10.1177/15579883221087532>.
  22. Canguven O, Khalafalla K, Al Ansari A. Low-intensity extracorporeal shockwave therapy for erectile dysfunction. *Arab J Urol* 2021;19:340-345. <https://doi.org/10.1080/2090598X.2021.1948158>.
  23. Kafka D, Biernikiewicz M, Gebala J, Bielecka-Jarząbek G, Zdrojowy R, Pilecki W. Efficacy of low energy shock-wave therapy generated using an electrohydraulic device in the treatment of ED: A systematic review and meta-analysis of randomized controlled trials. *Arch Esp Urol* 2021;74:606-617.
  24. Ochoa A, Guillot-Tantay C, Misrai V, Rouprêt M. [Low-intensity extracorporeal shock wave therapy for erectile dysfunction: A systematic review]. *Prog Urol* 2021;31:506-518. French.
  25. Dong L, Chang D, Zhang X et al. Effect of Low-intensity extracorporeal shock wave on the treatment of erectile dysfunction: a systematic review and meta-analysis. *Am J Mens Health* 2019;13:1557988319846749. <https://doi.org/10.1177/1557988319846749>.
  26. Sokolakis I, Hatzichristodoulou G. Clinical studies on low intensity extracorporeal shockwave therapy for erectile dysfunction: a systematic review and meta-analysis of randomised controlled trials. *Int J Impot Res* 2019;31:177-194. <https://doi.org/10.1038/s41443-019-0117-z>.
  27. Campbell JD, Trock BJ, Oppenheim AR, Anusionwu I, Gor RA, Burnett AL. Meta-analysis of randomized controlled trials that assess the efficacy of low-intensity shockwave therapy for the treatment of erectile dysfunction. *Ther Adv Urol* 2019;11:1756287219838364. <https://doi.org/10.1177/1756287219838364>.
  28. Man L, Li G. Low-intensity extracorporeal shock wave therapy for erectile dysfunction: a systematic review and meta-analysis. *Urology* 2018;119:97-103. <https://doi.org/10.1016/j.urology.2017.09.011>.
  29. Angulo JC, Arance I, de Las Heras MM, Meilán E, Esquinas C, Andrés EM. Efficacy of low-intensity shock wave therapy for erectile dysfunction: A systematic review and meta-analysis. *Actas Urol Esp* 2017;41:479-490. <https://doi.org/10.1016/j.acuro.2016.07.005>.
  30. Lu Z, Lin G, Reed-Maldonado A, Wang C, Lee YC, Lue TF. Low-intensity extracorporeal shock wave treatment improves erectile function: a systematic review and meta-analysis. *Eur Urol* 2017;71:223-233. <https://doi.org/10.1016/j.eururo.2016.05.050>.
  31. Clavijo RI, Kohn TP, Kohn JR, Ramasamy R. Effects of Low-intensity extracorporeal shockwave therapy on erectile dysfunction: a systematic review and meta-analysis. *J Sex Med* 2017;14:27-35. <https://doi.org/10.1016/j.jsxm.2016.11.001>.
  32. EAU guidelines on sexual and reproductive health. [https://d56bochluxqz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Sexual-and-Reproductive-Health-2024\\_2024-05-23-101205\\_nmmbi.pdf](https://d56bochluxqz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Sexual-and-Reproductive-Health-2024_2024-05-23-101205_nmmbi.pdf) (10 December 2024, date last accessed).
  33. Clinically localized prostate cancer: AUA/ASTRO guideline (2022) <https://www.auanet.org/guidelines-and-quality/guidelines/clinically-localized-prostate-cancer-uaa/astro-guideline-2022> (10 December 2024, date last accessed).
  34. Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. <https://doi.org/10.1136/bmj.n71>.
  35. Chen X, Huang HW, Zhu XB, et al. [Focused low-intensity extracorporeal shock wave therapy for erectile dysfunction: Preliminary observation of 32 cases]. *Zhonghua Nan Ke Xue* 2018;24:529-532. Chinese.
  36. Katz JE, Molina ML, Clavijo R, Prakash NS, Ramasamy R. A Phase 2 randomized trial to evaluate different dose regimens of low-intensity extracorporeal shockwave therapy for erectile dysfunction: clinical trial update. *Eur Urol Focus* 2018;4:336-337. <https://doi.org/10.1016/j.euf.2018.07.011>.
  37. Patel P, Huang C, Molina M, Ramasamy R. Clinical trial update on shockwave therapy and future of erectile function restoration. *Int J Impot Res* 2019;31:206-208. <https://doi.org/10.1038/s41443-019-0115-1>.
  38. Patel P, Katz J, Lokeshwar SD et al. Phase II randomized, clinical trial evaluating 2 schedules of low-intensity shockwave therapy for the treatment of erectile dysfunction. *Sex Med* 2020;8:214-222. <https://doi.org/10.1016/j.esxm.2020.01.010>.
  39. Ghahhari J, De Nunzio C, Lombardo R et al. Shockwave therapy for erectile dysfunction: which gives the best results? a retrospective national, multi-institutional comparative study of different shockwave technologies. *Surg Technol Int* 2022;40:213-218. <https://doi.org/10.52198/22.STI.40.UR1556>.
  40. Manfredi C, Arcaniolo D, Amicuzi U et al. Impact of extracorporeal shockwave therapy for erectile dysfunction and Peyronie's disease on reproductive and hormonal function. *Andrology* 2022;10:1368-1375. <https://doi.org/10.1111/andr.13240>.
  41. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. *Urology* 1997;49:822-30. [https://doi.org/10.1016/s0090-4295\(97\)00238-0](https://doi.org/10.1016/s0090-4295(97)00238-0).
  42. Vardi Y, Appel B, Jacob G, Massarwi O, Gruenwald I. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. *Eur Urol* 2010;58:243-8. <https://doi.org/10.1016/j.eururo.2010.04.004>.
  43. Oginski N, Apel H, Richterstetter M et al. Analysis of the impact of clinical factors on low-intensity extracorporeal shockwave therapy for erectile dysfunction. *Urol Int* 2022;106:1041-1049. <https://doi.org/10.1159/000520705>.
  44. Frey A, Sønksen J, Fode M. Low-intensity extracorporeal shockwave therapy in the treatment of postprostatectomy erectile dysfunction: a pilot study. *Scand J Urol* 2016;50:123-7. <https://doi.org/10.3109/21681805.2015.1100675>.
  45. Musa ZS, El-Assmy A, Shokry AM, Shokeir AA, Zween T, Al-Kenawy MR. Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders. *Arab J Urol* 2019;18:54-58. <https://doi.org/10.1080/2090598X.2019.1688072>.
  46. Kim KS, Jeong HC, Choi SW et al. Electromagnetic low-intensity extracorporeal shock wave therapy in patients with erectile dysfunction: a sham-controlled, double-blind, randomized prospective study. *World J Mens Health* 2020;38:236-242. <https://doi.org/10.5534/wjmh.190130>.
  47. Sandoval-Salinas C, Saffon JP, Martínez JM, Corredor HA, Gallego A. Are radial pressure waves effective for the treatment of moderate or mild to moderate erectile dysfunction? a randomized

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

- sham therapy controlled clinical trial. *J Sex Med* 2022;19:738-744. <https://doi.org/10.1016/j.jsxm.2022.02.010>.
48. Tao R, Chen J, Wang D, et al. The efficacy of Li-ESWT combined with VED in diabetic ED patients unresponsive to PDE5is: a single-center, randomized clinical trial. *Front Endocrinol* 2022;13:937958. <https://doi.org/10.3389/fendo.2022.937958>.
  49. Bryk DJ, Murthy PB, Ericson KJ, Shoskes DA. Radial wave therapy does not improve early recovery of erectile function after nerve-sparing radical prostatectomy: a prospective trial. *Transl Androl Urol* 2023;12:209-216. <https://doi.org/10.21037/tau-22-310>.
  50. Islam R, Rahaman KS, Hawlader MDH. Efficacy of low-intensity extra corporal shockwave therapy (li-eswt) in patients with erectile dysfunction. *J Family Reprod Health* 2023;17:93-99. <https://doi.org/10.18502/jfrh.v17i2.12872>.
  51. Trishch VI, Mysak AI, Trishch AI, Mandzii AP. Assessment of the treatment effectiveness of men with mild and medium degree of erectile dysfunction. *Pol Merkur Lekarski* 2024;52:79-86. <https://doi.org/10.36740/Merkur202401113>.
  52. Heritier SR, GebSKI VJ, Keech AC. Inclusion of patients in clinical trial analysis: the intention-to-treat principle. *Med J Aust* 2003;179:438-40. <https://doi.org/10.5694/j.1326-5377.2003.tb05627.x>.
  53. Gupta SK. Intention-to-treat concept: A review. *Perspect Clin Res* 2011;2:109-112. <https://doi.org/10.4103/2229-3485.83221>.
  54. McCoy CE. Understanding the intention-to-treat principle in randomized controlled trials. *West J Emerg Med* 2017;18:1075-1078. <https://doi.org/10.5811/westjem.2017.8.35985>.
  55. Nguyen M. (2020). A Guide on Data Analysis. Bookdown. [https://bookdown.org/mike/data\\_analysis/](https://bookdown.org/mike/data_analysis/) (10 December 2024, date last accessed).
  56. European Medicines Agency. Guideline on Missing Data in Confirmatory Clinical Trials. <https://www.tga.gov.au/sites/default/files/2024-06/guideline-missing-data-confirmatory-clinical-trials-ema.pdf> (10 December 2024, date last accessed).
  57. U.S. Food and Drug Administration. E9(R1) statistical principles for clinical trials: Addendum: Estimands and sensitivity analysis in clinical trials [Internet] in 2021 <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e9r1-statistical-principles-clinical-trials-addendum-estimands-and-sensitivity-analysis-clinical> (10 December 2024, date last accessed).
  58. European Medicines Agency. ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials [Internet] in 2020 [https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf) (10 December 2024, date last accessed).
  59. Cro S, Kahan BC, Rehal S, Chis Ster A, Carpenter JR, White IR, Cornelius VR. Evaluating how clear the questions being investigated in randomised trials are: systematic review of estimands. *BMJ* 2022;378:220146. <https://doi.org/10.1136/bmj-2022-070146>.
  60. Karakose A, Yitgin Y. Penile rehabilitation with low-intensity extracorporeal shock wave therapy in patients after prostate cancer surgery. Early physiological changes and postoperative follow-up outcomes. *Int J Clin Pract* 2021;75:e14804. <https://doi.org/10.1111/ijcp.14804>.
  61. Verze P, Capece M, Creta M et al. Efficacy and safety of low-intensity shockwave therapy plus tadalafil 5 mg once daily in men with type 2 diabetes mellitus and erectile dysfunction: a matched-pair comparison study. *Asian J Androl* 2020;22:379-382. [https://doi.org/10.4103/aja.aja\\_121\\_19](https://doi.org/10.4103/aja.aja_121_19).
  62. Kalyvianakis D, Mykoniatis I, Pyrgidis N, Kapoteli P, Zilotis F, Hatzichristou D. The effect of combination treatment with low-intensity shockwave therapy and daily tadalafil on severe erectile dysfunction: a double-blind, randomized, sham-controlled clinical trial. *J Sex Med* 2024;21:533-538. <https://doi.org/10.1093/jsexmed/qdae038>.
  63. Kennady EH, Bryk DJ, Ali MM et al. Low-intensity shockwave therapy improves baseline erectile function: a randomized sham-controlled crossover trial. *Sex Med* 2023;11:qfad053. <https://doi.org/10.1093/sexmed/qfad053>.
  64. Kalyvianakis D, Mykoniatis I, Pyrgidis N et al. The effect of low-intensity shock wave therapy on moderate erectile dysfunction: a double-blind, randomized, sham-controlled clinical trial. *J Urol* 2022;208:388-395. <https://doi.org/10.1097/JU.0000000000002684>.
  65. Motil I, Macic D, Sramkova K, Jarkovsky J, Sramkova T. Linear low-intensity extracorporeal shockwave therapy as a method for penile rehabilitation in erectile dysfunction patients after radical prostatectomy: a randomized, single-blinded, sham-controlled clinical trial. *Urol Int* 2022;106:1050-1055. <https://doi.org/10.1159/000525973>.
  66. Ong WLK, Lechmiannandan S, Lim YL, Manoharan D, Lee SB. Early outcomes of short-course low intensity shockwave therapy (LiSWT) for erectile dysfunction: A prospective, randomized, double-blinded, sham-controlled study in Malaysia. *Andrologia* 2022;54:29518. <https://doi.org/10.1111/and.14518>.
  67. Ladegaard PBJ, Mortensen J, Skov-Jepesen SM, Lund L. Erectile dysfunction a prospective randomized placebo-controlled study evaluating the effect of low-intensity extracorporeal shockwave therapy (LI-ESWT) in men with erectile dysfunction following radical prostatectomy. *Sex Med* 2021;9:100338. <https://doi.org/10.1016/j.esxm.2021.100338>.
  68. Shendy WS, Elsoghier OM, El Semary MM et al. Effect of low-intensity extracorporeal shock wave therapy on diabetic erectile dysfunction: randomised control trial. *Andrologia* 2021;53:e13997. <https://doi.org/10.1111/and.13997>.
  69. Sramkova T, Motil I, Jarkovsky J, Sramkova K. Erectile dysfunction treatment using focused linear low-intensity extracorporeal shockwaves: single-blind, sham-controlled, randomized clinical trial. *Urol Int* 2020;104:417-424. <https://doi.org/10.1159/000504788>.
  70. Yamaçake KGR, Carneiro F, Cury J, et al. Low-intensity shockwave therapy for erectile dysfunction in kidney transplant recipients. A prospective, randomized, double blinded, sham-controlled study with evaluation by penile Doppler ultrasonography. *Int J Impot Res* 2019;31:195-203. <https://doi.org/10.1038/s41443-018-0062-2>.
  71. Fojecki GL, Tiessen S, Othter PJ. Effect of low-energy linear shockwave therapy on erectile dysfunction-a double-blinded, sham-controlled, randomized clinical trial. *J Sex Med* 2017;14:106-112. <https://doi.org/10.1016/j.jsxm.2016.11.307>.
  72. Kalyvianakis D, Hatzichristou D. Low-intensity shockwave therapy improves hemodynamic parameters in patients with vasculogenic erectile dysfunction: a triplex ultrasonography-based sham-controlled trial. *J Sex Med* 2017;14:891-897. <https://doi.org/10.1016/j.jsxm.2017.05.012>.
  73. Srimi VS, Reddy RK, Shultz T, Denes B. Low intensity extracorporeal shockwave therapy for erectile dysfunction: a study in an Indian population. *Can J Urol* 2015;22:7614-22.
  74. Yee CH, Chan ES, Hou SS, Ng CF. Extracorporeal shockwave therapy in the treatment of erectile dysfunction: a prospective, randomized, double-blinded, placebo controlled study. *Int J Urol* 2014;21:1041-5. <https://doi.org/10.1111/iju.12506>.
  75. Vardi Y, Appel B, Kilchevsky A, Gruenwald I. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. *J Urol* 2012;187:1769-75. <https://doi.org/10.1016/j.juro.2011.12.117>.
  76. Katz JE, Clavijo RI, Rizk P, Ramasamy R. The basic physics of waves, soundwaves, and shockwaves for erectile dysfunction. *Sex Med Rev* 2020;8:100-105. <https://doi.org/10.1016/j.sxmr.2019.09.004>.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

77. Perez C, Chen H, Matula TJ, Karzova M, Khokhlova VA. Acoustic field characterization of the Duolith: measurements and modeling of a clinical shock wave therapy device. *J Acoust Soc Am* 2013;134:1663-174. <https://doi.org/10.1121/1.4812885>
78. AIP publishing license number 5915831327133. <https://s1000.copyright.com/CustomAdmin/PLF.jsp?ref=601f42dd-5e1e-4ba5-a50a-4a9e313f4031> (10 December 2024, date last accessed).
79. Gerdesmeyer L, Maier M, Haake M, Schmitz C. [Physical-technical principles of extracorporeal shockwave therapy (ESWT)]. *Orthopade* 2002;31:610-617. German. <https://doi.org/10.1007/s00132-002-0319-8>.
80. Schmitz C, Császár NB, Rompe JD, Chaves H, Furia JP. Treatment of chronic plantar fasciopathy with extracorporeal shock waves (review). *J Orthop Surg Res* 2013;8:31. <https://doi.org/10.1186/1749-799X-8-31>.
81. Jokinen LLJ, Wuerfel T, Schmitz C. Opinion: Application of extracorporeal shock wave therapy in nervous system diseases. *Front Neurol* 2023;14:1281684. <https://doi.org/10.3389/fneur.2023.1281684>.
82. Porst H. Review of the current status of low intensity extracorporeal shockwave therapy (Li-ESWT) in erectile dysfunction (ED), Peyronie's disease (PD), and sexual rehabilitation after radical prostatectomy with special focus on technical aspects of the different marketed ESWT devices including personal experiences in 350 patients. *Sex Med Rev* 2021;9:93-122. <https://doi.org/10.1016/j.sxmr.2020.01.006>.
83. Császár NB, Angstman NB, Milz S et al. Radial shock wave devices generate cavitation. *PLoS One* 2015;10:1640541. <https://doi.org/10.1371/journal.pone.0140541>.
84. Chitnis PV, Cleveland R. Acoustic and cavitation fields of shock wave therapy devices. *AIP Conf Proc* 2006;829:440-444.
85. Brennen CA. Cavitation and bubble dynamics. Cambridge: Cambridge University Press, 2014.
86. Sternecker K, Geist J, Beggel S et al. Exposure of zebra mussels to extracorporeal shock waves demonstrates formation of new mineralized tissue inside and outside the focus zone. *Biol Open* 2018;7:bio033258. <https://doi.org/10.1242/bio.033258>.
87. Ogden JA, Tóth-Kischkat A, Schultheiss R. Principles of shock wave therapy. *Clin Orthop Relat Res* 2001;8:17. <https://doi.org/10.1097/00003086-200106000-00003>.
88. IEC-61846:1998: Ultrasonics - pressure pulse lithotripters - characteristics of fields. International Electrotechnical Commission, Geneva, Switzerland, 1998.
89. Hochstrasser T, Frank HG, Schmitz C. Dose-dependent and cell type-specific cell death and proliferation following in vitro exposure to radial extracorporeal shock waves. *Sci Rep* 2016;6:30637. <https://doi.org/10.1038/srep30637>.
90. Angstman NB, Kiessling MC, Frank HG, Schmitz C. High interindividual variability in dose-dependent reduction in speed of movement after exposing *C. elegans* to shock waves. *Front Behav Neurosci* 2015;9:12. <https://doi.org/10.3389/fnbeh.2015.00012>.
91. Schelling G, Delius M, Gschwender M, Grafe P, Gambihler S. Extracorporeal shock waves stimulate frog sciatic nerves indirectly via a cavitation-mediated mechanism. *Biophys J*. 1994;66:133-140. [https://doi.org/10.1016/S0006-3495\(94\)80758-1](https://doi.org/10.1016/S0006-3495(94)80758-1).
92. Delius M, Gambihler S. Effect of shock waves on gallstones and materials. In Paumgartner G, Sauerbruch T, Sackmann M, Burhenne H. (eds) Lithotripsy and related techniques for gallstone treatment. St. Louis: Mosby-Year Book 1992;27-33.
93. Reinhardt N, Wegenaer J, de la Fuente M. Influence of the pulse repetition rate on the acoustic output of ballistic pressure wave devices. *Sci Rep* 2022;12:18060. <https://doi.org/10.1038/s41598-022-21595-5>.
94. Konchugova TV, Kulchitskaya DB, Kiyatkin VA, Gushchina NV. [Transcerebral magnetic and shock wave therapy in correction of erectile dysfunction]. *Vopr Kurortol Fizioter Lech Fiz Kult* 2020;97:60-67. Russian. <https://doi.org/10.17116/kurort20209703160>.
95. Lau W, Shum CF, Lua HCA, Teo CPC. Low-intensity shockwave therapy in the management of erectile dysfunction in Singapore. *Ann Acad Med Singap* 2021;50:652-654. <https://doi.org/10.47102/annals-acadmedsg.202151>.
96. Akande TO, Akinwunmi OM, Adebayo SA, Akinyinka AO, Shittu OB. Efficacy and safety of low-intensity extracorporeal shockwave therapy for treatment of vascular erectile dysfunction in Nigerian men: report of a study in Ibadan, south-west Nigeria. *Ann Ib Postgrad Med* 2021;19:8-14.
97. Zanaty F, Badawy A, Kotb H, Elsarfy F, Salman B. Efficacy and safety of low-intensity extracorporeal shock wave therapy versus on-demand tadalafil for erectile dysfunction. *Arab J Urol* 2022;20:189-194. <https://doi.org/10.1080/2090598X.2022.2090134>.
98. Rubino M, Ricapito A, Finati M et al. Impact of low-intensity extracorporeal shockwave therapy on vascular parameters and sexual function in patients with arteriogenic erectile dysfunction. *Asian J Androl* 2024;26:344-348. <https://doi.org/10.4103/aja202384>.
99. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996;17:1-12. [https://doi.org/10.1016/0197-2456\(95\)00134-4](https://doi.org/10.1016/0197-2456(95)00134-4).
100. Verhagen AP, de Vet HC, de Bie RA et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. *J Clin Epidemiol* 1998;51:1235-1241. [https://doi.org/10.1016/s0895-4356\(98\)00131-0](https://doi.org/10.1016/s0895-4356(98)00131-0).
101. Blobaum P. Physiotherapy Evidence Database (PEDro). *J Med Libr Assoc* 2006;94:477-478.
102. Chalmers TC, Smith H Jr, Blackburn B et al. A method for assessing the quality of a randomized control trial. *Control Clin Trials* 1981;2:31-49. [https://doi.org/10.1016/0197-2456\(81\)90056-8](https://doi.org/10.1016/0197-2456(81)90056-8).
103. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *J Epidemiol Community Health* 1998;52:377-384. <https://jech.bmj.com/content/52/6/377>.
104. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *PLoS Med* 2010;7:2500251. <https://doi.org/10.1371/journal.pmed.1000251>.
105. Estimands: treatment strategies for handling intercurrent events. <https://www.quanticate.com/blog/estimands-clinical-trials> (10 December 2024, date last accessed).
106. Ortac M, Özmez A, Cilesiz NC, Demirelli E, Kadioğlu A. The impact of extracorporeal shock wave therapy for the treatment of young patients with vasculogenic mild erectile dysfunction: A prospective randomized single-blind, sham controlled study. *Andrology* 2021;9:1571-1578. <https://doi.org/10.1111/andr.13007>.
107. Scropo FI, Pezzoni F, Gaeta F et al. Li-ESWT improves hemodynamic parameters thus suggesting neoangiogenesis in patients with vascular erectile dysfunction. *Int J Impot Res* 2022;34:237-242. <https://doi.org/10.1038/s41443-021-00411-0>.
108. Ayala HAC, Cuartas JPS, Cleves DC. Impact on the quality of erections after completing a low-intensity extracorporeal shock wave treatment cycle on a group of 710 patients. *Adv Urol* 2017;2017:1843687. <https://doi.org/10.1155/2017/1843687>.
109. Jang SW, Lee EH, Chun SY et al. Comparison of the efficacy of the early LI-SWT plus daily tadalafil with daily tadalafil only as penile rehabilitation for postprostatectomy erectile dysfunction. *Int J Impot Res* 2023;35:447-453. <https://doi.org/10.1038/s41443-022-00560-w>.
110. Imputation in R: Top 3 ways for imputing missing data. <https://www.appsilon.com/post/imputation-in-r> (10 December 2024, date last accessed).

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

111. The R project for statistical computing. <https://www.r-project.org/> (10 December 2024, date last accessed).
112. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *Amer Statist Assoc* 1958;53:457-481. <https://doi.10.2307/2281868>.
113. Gibbons JP, Zeng N, Bayan A, Walker ML, Farrington B, Young SW. No difference in 10-year clinical or radiographic outcomes between kinematic and mechanical alignment in TKA: a randomized trial. *Clin Orthop Relat Res* 2024 Aug 14: online ahead of print. <https://doi.10.1097/CORR.0000000000003193>.
114. Ayoola AS, Charters MA, Raja HM et al. Survivorship of primary nexgen knee replacement: comparing cementless trabecular metal to other designs of tibial component. *J Knee Surg* 2024;37:949-958. <https://doi.10.1055/a-2376-6889>.
115. Jung WH, Sahu V, Seo M, Takeuchi R. Cartilage regeneration and long term survival in medial OA knee patients treated with HTO and OATS. *J Orthop* 2024;57:120-126. <https://doi.10.1016/j.jor.2024.06.024>.
116. Morgan JPM, Hamm M, Schmitz C, Brem MH. Return to play after treating acute muscle injuries in elite football players with radial extracorporeal shock wave therapy. *J Orthop Surg Res* 2021;16:708. <https://doi.10.1186/s13018-021-02853-0>.
117. Guo X, Li L, Yan Z, et al. Efficacy and safety of treating chronic nonspecific low back pain with radial extracorporeal shock wave therapy (rESWT), rESWT combined with celecoxib and eperisone (C + E) or C + E alone: a prospective, randomized trial. *J Orthop Surg Res* 2021;16:705. <https://doi.10.1186/s13018-021-02848-x>.
118. Langendorf EK, Klein A, Drees P, Rommens PM, Mattyasovszky SG, Ritz U. Exposure to radial extracorporeal shockwaves induces muscle regeneration after muscle injury in a surgical rat model. *J Orthop Res* 2020;38:1386-1397. <https://doi.10.1002/jor.24564>.

# Extracorporeal shock wave therapy for erectile dysfunction: rethinking study design, implementation, and analysis

Janak Desai, Eric Huyghe, Gayle D. Maffulli,  
Carmen Nussbaum-Krammer, Jessica Tittelmeier, Christoph Schmitz

## Supplementary Data

This Online Supplement contains the raw data of 55 variables extracted from 87 clinical trials on extracorporeal shock wave therapy for erectile dysfunction published until September 27, 2024.

### Abbreviations used in Supplementary Data:

3D	Three-dimensional
BOCF	Baseline observation carried forward
C	Control treatment
D	Day
ED <sup>+</sup>	Positive energy density
ED <sup>total</sup>	Total energy density
EH	Electrohydraulic
EM	Electromagnetic
EM-B	Electromagnetic-ballistic
ESW	Extracorporeal shock wave
ESWT	Extracorporeal shock wave therapy
F	Focused
Hz	Hertz
IIEF-EF	International Index of Erectile Function - Erectile Domain
ITT	Intent-to-treat
KL	Kilovolt
L	Linear
mJ/mm <sup>2</sup>	Millijoule per squared millimeter
n.a.	Not applicable
n.s.	Not specified
P-B	Pneumatic-ballistic
PDE5i	Phosphodiesterase-5 inhibitors
PE	Piezoelectric
PRP	Platelet derived plasma
R	Radial
Ref	Reference
RCT	Randomized controlled trial
SD	Standard deviation
TMS	Transcranial magnetic stimulation
U	Unfocused
V	Variable
W	Week

Name	Variable
<b>A - General information</b>	
V1	Name of the first author
V2	Year of publication
V3	The country (or countries) in which the clinical trial was performed were specified (country name(s) / not specified)
V4	The type of investigated erectile dysfunction was specified (vasculogenic / organic / post-radical prostatectomy / diverse / not specified)
V5	The patients were non-responders to PDE5i (yes / no / both / not specified)
V6	The blood testosterone level of all patients enrolled in the trial was normal (yes / no / not specified)
V7	Testosterone replacement therapy was performed in case of testosterone deficiency (yes / no / not applicable)
V8	The IIEF-EF score was determined to enable comparison of treatment outcome with other studies on ESWT for ED, including the first description in the literature (yes / no)
V9	The type of clinical trial was specified (case series / cohort study / RCT)
V10	Control groups were specified (not applicable / 1 / 2 / 3 / etc.)
V11	It was specified whether the data were prospectively or retrospectively collected (prospective / retrospective / not specified)
V12	The time post-baseline or post-treatment [weeks] at which the primary endpoint was determined was specified. (Note: in this systematic review sometimes data from a different time point were used for analysis in order to keep the times post-treatment as homogeneous as possible.)
V13	Additional follow-up times [weeks or months] were reported (values / not applicable)
<b>B – ESWT device used</b>	
V14	The exact name of the used device was specified (name / not specified)
V15	The manufacturer's name, country and city of the headquarter were specified (data / not specified)
V16	The type of generated ESWs was specified (focused (F) / unfocused (U) / linear (L) / radial (R) / not specified)
V17	The technology of ESW generation was specified (electrohydraulic (EH) / electromagnetic (EM) / piezoelectric (PE) / electromagnetic-ballistic (EM-B) / pneumatic-ballistic (P-B) / not specified)
<b>C – (Main) ESWT group</b>	
V18	The number of patients in the (main) ESWT group was specified (number / not specified)
V19	The number of patients in the (main) ESWT group lost to follow-up was specified (number / not specified)
V20	The age of the patients [years] in the (main) ESWT group was specified (minimum / median / mean / standard deviation / maximum / interquartile distance / not specified)
V21	The duration of erectile dysfunction before baseline [months] of the patients in the (main) ESWT group was specified (minimum / median / mean / standard deviation / maximum / interquartile distance / not specified)
V22	The number of treatment sessions was specified (number / not specified)
V23	The time sequence of the treatment sessions was specified (weeks and number of sessions per week / not specified)
V24	The number of ESWs per treatment session was specified (number of treatment regions distributed over the penis times number of ESWs per treatment region / not specified)
V25	The type of the reported energy density of the ESWs was specified ( $ED^+$ / $ED^{total}$ / not specified whether $ED^+$ or $ED^{total}$ )
V26	The energy density of the ESWs [ $mJ/mm^2$ ] was specified (value / not specified).
V27	Alternatively, there was another description of the energy settings of ESWs (KV / mJ / Bar)
V28	The three-dimensional (3D) acoustic pressure field of the applied ESWs (i.e., for the device settings used in the clinical trial) was analyzed, including determination of the 3D regional distribution of the peak positive pressure, peak negative pressure and the resulting energy density (yes / no)
V29	Alternatively, the report referred to a publication in which the 3D acoustic pressure field of the applied ESWs (i.e., for the device settings used in the clinical trial) was analyzed as described in V28 (yes / no)
V30	The frequency of the applied ESWs [Hz] was specified (value / not specified)
V31	Additional treatment(s) next to ESWT were specified (additional treatment(s) / no additional treatment(s))

Name	Variable
<b>D – First control group (if applicable)</b>	
V32	Data corresponding to V18
V33	Data corresponding to V19
V34	Data corresponding to V20
V35	Data corresponding to V21
V36	The treatment(s) of the patients in the first control group were specified (treatment(s) / not specified)
<b>E – Second control group (if applicable)</b>	
V37	Data corresponding to V18
V38	Data corresponding to V19
V39	Data corresponding to V20
V40	Data corresponding to V21
V41	Data corresponding to V36
<b>F – Third control group (if applicable)</b>	
V42	Data corresponding to V18
V43	Data corresponding to V19
V44	Data corresponding to V20
V45	Data corresponding to V21
V46	Data corresponding to V36
<b>G – Statistical analysis</b>	
V47	An Intent-to-Treat analysis was performed (yes / no)
V48	There were missing data due to patients lost to follow-up (yes / no)
V49	Missing data imputation was performed (yes / no / not applicable as no patient was lost to follow-up)
V50	The method(s) used for missing data imputation were specified (method(s) / not applicable)
V51	An estimand strategy for handling intercurrent events was developed (yes / no)
V52	The reported data are suitable for calculating an average mean $\pm$ SD of mean IIEF-EF data reported in different clinical trials at baseline and at follow-up (i.e., mean IIEF-EF values at baseline and at follow-up must be reported) (data)
V53	The data were suitable for a meta-analysis (i.e., mean, SD and number of patients in the ESWT group and the main control group were available at baseline and at follow-up, and use or non-use of ESWT was the only difference between the groups (sham treatment was considered non-use of ESWT)) (yes / no / not applicable for case series)
<b>H – Therapeutic outcome</b>	
V54	ESWT resulted in a statistically significant improvement of erectile dysfunction compared to baseline (yes / no / not applicable)
V55	ESWT resulted in a statistically significant improvement of erectile dysfunction compared to sham or control treatment (not applicable for case series; A, ESWT+, C-, ESWT > C; B, ESWT+, C+, ESWT > C; C, ESWT+, C+, ESWT = C; D, ESWT-, C-, ESWT = C; E, ESWT-, C+, ESWT < C)

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Ref	V1	V2	V3	V4	V5	V6	V7	V8
1	İbis	2024	Turkey	Not specified	Yes	Yes	Not applicable	No
2	Kalyvianakis	2024	Greece	Vasculogenic	No	Yes	Not applicable	Yes
3	Kaynak	2024	Turkey	Organic	Both	Not tested	Not considered	No
4	Rubino	2024	Italy	Vasculogenic	No	Yes	Not applicable	No
5	Trishch	2024	Ukraine	Not specified	No	Not tested	Not considered	Yes
6	Bayraktar	2023	Turkey	Not specified	Yes	Yes	Not applicable	No
7	Bryk	2023	USA	P-RP	No	Not tested	Not considered	No
8	Islam	2023	Bangladesh	Not specified	No	Not tested	Not considered	No
9	Jang	2023	Korea	P-RP	No	Not tested	Not considered	No
10	Kennady	2023	USA	Organic	Both	Yes	Not applicable	No
11	Kohada	2023	Japan	P-RP	No	Not tested	Not considered	Yes
12	Kurosawa	2023	Japan	Diverse	No	Yes	Not applicable	No
13	Ma	2023	China	Organic	No	Not tested	Not considered	No
14	Vena	2023	Italy	Organic	Yes	Yes	Not applicable	Yes
15	Wang	2023	China	Diverse	No	Not tested	Not considered	Yes
16	Cocci	2022	Italy	<sup>1</sup>	No	Yes	Not applicable	No
17	Daneshwar	2022	Malaysia	<sup>2</sup>	No	Not tested	Not considered	No
18	Ergün	2022	Turkey	Vasculogenic	Yes	Not tested	Not considered	No
19	Gallo	2022	Italy	Not specified	No	Yes	Not applicable	Yes
20	Geyik	2022	Turkey	Not specified	No	Yes	Not applicable	Yes
21	Kalyvianakis	2022	Greece	Vasculogenic	No	Yes	Not applicable	Yes
22	Motil	2022	Czech republic	P-RP	No	Yes	Not applicable	No
23	Mykoniatis	2022	Greece	Vasculogenic	No	Yes	Not applicable	Yes
24	Oginski	2022	Germany	Organic	Yes	Not tested	Not considered	No
25	Ong	2022	Malaysia	Diverse	No	Not tested	Not considered	No
26	Sandoval-Salinas	2022	Colombia	Organic	No	Not tested	Not considered	Yes
27	Scropo	2022	Italy	Vasculogenic	Yes	Yes	Not applicable	No
28	Tao	2022	China	Vasculogenic	Yes	Yes	Not applicable	Yes
29	Zanaty	2022	Egypt	Organic	No	Yes	Not applicable	No
30	Adeldaeim	2021	Egypt	Vasculogenic	No	No	Yes	No
31	Akande	2021	Nigeria	Vasculogenic	No	Not tested	Not considered	No
32	Caretta	2021	Italy	Organic	No	Yes	Not applicable	No
33	Chung (follow-up)	2021	Australia	Vasculogenic	No	Not tested	Not considered	No
34	Geyik	2021	Turkey	Diverse	Yes	Yes	Not applicable	Yes
35	Karakose	2021	Turkey	P-RP	No	Not tested	Not considered	No
36	Ladegaard	2021	Denmark	P-RP	No	Not tested	Not considered	No
37	Lau	2021	Singapore	Diverse	No	Yes	Not applicable	No
38	Lei	2021	China	Diverse	No	Not tested	Not considered	No
39	Ortac	2021	Turkey	Vasculogenic	No	Yes	Not applicable	Yes
40	Palmieri	2021	Italy	Vasculogenic	Yes	Not tested	Not considered	Yes
41	Shendy	2021	Egypt	Vasculogenic	No	Not tested	Not considered	Yes
42	Tzou	2021	Taiwan	Diverse	Yes	Yes	Not applicable	No
43	Vinay	2021	Spain	Diverse	Yes	Not tested	Not considered	Yes
44	Baccaglioni	2020	Brazil	P-RP	No	Not tested	Not considered	No
45	Eryilmaz	2020	Turkey	Vasculogenic	Yes	Yes	Not applicable	No
46	Huang	2020	China	Diverse	No	Yes	Not applicable	No
47	Kalyvianakis	2020	Greece	Vasculogenic	No	Not tested	Not considered	Yes
48	Konchugova	2020	Russia	Vasculogenic	No	Not tested	Not considered	No
49	Lurz	2020	USA	Vasculogenic	No	Yes	Not applicable	Yes
50	Inoue	2020	Japan	P-RP	No	Yes	Not applicable	No

<sup>1</sup> Priapism-induced ED (45 days post-emergency management)

<sup>2</sup> ED on the basis of chronic pelvic pain syndrome

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Ref	V1	V2	V3	V4	V5	V6	V7	V8
51	Kim	2020	Korea	Not specified	No	Not tested	Not considered	Yes
52	Patel	2020	USA	Organic	No	Yes	Not applicable	Yes
53	Verze	2020	Italy	Vasculogenic	No	Not tested	Not considered	No
54	Wang	2020	China	Organic	Both	Yes	Not applicable	Yes
55	Wu	2020	USA	Vasculogenic	No	Not tested	Not considered	No
56	Zasieda	2020	Ukraine	<sup>3</sup>	No	Yes	Not applicable	No
57	Costa	2019	Portugal	Organic	No	Not tested	Not considered	No
58	Musa	2019	Egypt	Vasculogenic	Yes	No	Yes	<sup>4</sup>
59	Sramkova	2019	Czech republic	Vasculogenic	No	Yes	Not applicable	No
60	Vita	2019	Italy	Vasculogenic	Yes	Yes	Not applicable	No
61	Wang	2019	Taiwan	<sup>5</sup>	Yes	Not tested	Not considered	No
62	Yamaçake	2019	Brazil	<sup>6</sup>	No	Yes	Not applicable	No
63	De Oliveira	2018	Portugal	Diverse	No	Not tested	Not considered	No
64	Fojecki	2018	Demnark	Organic	No	Yes	Not applicable	Yes
65	Kalyvianakis	2018	Greece	Vasculogenic	No	Not tested	Not considered	Yes
66	Kitrey	2018	Israel	Diverse	No	Not tested	Not considered	<sup>4</sup>
67	Zewin	2018	Egypt	P-RP	No	Not tested	Not considered	No
68	Ayala	2017	Colombia / Spain	Vasculogenic	No	Not tested	Not considered	No
69	Fojecki	2017	Denmark	Organic	No	Yes	Not applicable	Yes
70	Kalyvianakis	2017	Greece	Vasculogenic	No	Not tested	Not considered	Yes
71	Tsai	2017	Taiwan	Organic	Yes	No	Yes	No
72	Bechara	2016	Argentina	Vasculogenic	Yes	Not tested	Not considered	<sup>7</sup>
73	Frey	2016	Denmark	P-RP	No	Not tested	Not considered	No
74	Hisasue	2016	Japan	Diverse	No	Yes	Not applicable	No
75	Kitrey	2016	Israel	Vasculogenic	Yes	Not tested	Not considered	Yes
76	Bechara	2015	Argentina	Vasculogenic	Yes	Not tested	Not considered	Yes
77	Chung	2015	Australia	Vasculogenic	No	Not tested	Not considered	No
78	Olsen	2015	Denmark	Organic	No	Not tested	Not considered	No
79	Pelayo-Nieto	2015	Mexico	Vasculogenic	No	Not tested	Not considered	Yes
80	Reisman	2015	<sup>8</sup>	Vasculogenic	No	Not tested	Not considered	Yes
81	Ruffo	2015	Italy	Organic	Yes	Not tested	Not considered	Yes
82	Srini	2015	India	Organic	No	Not tested	Not considered	Yes
83	Yee	2014	China	Organic	No	Not tested	Not considered	Yes
84	Gruenwald	2012	Israel	Vasculogenic	No	Not tested	Not considered	Yes
85	Palmieri	2012	Italy	ED + PD	No	Not tested	Not considered	No
86	Vardi	2012	Israel	Vasculogenic	No	Not tested	Not considered	Yes
87	Vardi	2010	Israel	Vasculogenic	No	Not tested	Not considered	Yes

<sup>3</sup> Veno-occlusive ED based on hypogonadotropic hypogonadism

<sup>4</sup> No IIEF-EF score at any follow-up time (M1, M6, M12, M18) reported

<sup>5</sup> post pelvic fractures associated with urethral injury

<sup>6</sup> ED in kidney transplant recipients (multifactorial)

<sup>7</sup> Only data of "LI-ESWT responders" reported (24 of 40 analyzed patients, with 50 patients included in the study and 10 patients lost to follow-up)

<sup>8</sup> Netherlands, Palestine, Lithuania and Czech Republic

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Ref	V9	V10	V11	V12	V13	V14	V15	V16	V17
1	Cohort study	2	Retrospective	27		Duolith SD1	Storz Medical	F	EM
2	RCT	1	Prospective	16		Aries 2	Dornier	F	EM
3	Case series	n.a.	Retrospective	52	208	Omnispec ED1000	Medispec	F	EH
4	Case series	n.a.	Retrospective	11	52	Ortho Gold 100	MTS	F	EH
5	Cohort study	2	Not specified	8		GentlePro	Zimmer	R	R
6	Case series <sup>9</sup>	n.a.	Retrospective	21	52	Not specified	Unknown	n.s.	n.s.
7	Cohort study	1	Prospective	12		enPulse Pro	Zimmer	R	R
8	Case series	n.a.	Prospective	7	52	BTL-6000	BTL	R	R
9	Cohort study	1	Prospective	24		Omnispec ED1000	Medispec	F	EH
10	RCT	1	Prospective	4		Duolith SD1	Storz Medical	F	EM
11	Cohort study	1	Retrospective	24		Omnispec ED1000	Medispec	F	EH
12	Cohort study	1	Retrospective	8		Omnispec ED1000	Medispec	F	EH
13	Case series	n.a.	Not specified	24	52	LGT-2510B	Longest	n.s.	n.s.
14	Case series	n.a.	Prospective	30		UroGold 100	MTS	F	EH
15	Cohort study	1	Prospective	13		Omnispec ED1000	Medispec	F	EH
16	Case series	n.a.	Prospective	20		Duolith SD1	Storz Medical	F	EM
17	Case series	n.a.	Prospective	10		Duolith SD1	Storz Medical	F	EM
18	Case series	n.a.	Retrospective	12		Not specified	Electronica Pagani	n.s.	n.s.
19	RCT	1	Prospective	24	52	Duolith SD1	Storz Medical	F	EM
20	Case series	n.a.	Retrospective	24		Renova	Direx	L	EM
21	RCT	1	Prospective	12		Aries 2	Dornier	F	EM
22	RCT	1	Prospective	24		Piezowave 2 linear	Richard Wolf	L	PE
23	RCT	1	Prospective	28		Aries 2	Dornier	F	EM
24	Case series	n.a.	Prospective	30		Duolith SD1	Storz Medical	F	EM
25	RCT	1	Prospective	24		Piezowave 2 linear	Richard Wolf	L	PE
26	RCT	1	Prospective	10		Masterpuls MP50	Storz Medical	R	R
27	Case series	n.a.	Prospective	n.s.		Duolith SD1	Storz Medical	F	EM
28	RCT	2	Prospective	12		ESWO-I 80 mm	SHME <sup>10</sup>	F	EM
29	Cohort study	1	Prospective	12		Piezowave 2 linear	Richard Wolf	L	PE
30	Case series	n.a.	Prospective	24		Piezowave 2 focused	Richard Wolf	F	PE
31	Case series	n.a.	Prospective	24		Omnispec ED1000	Medispec	F	EH
32	Case series	n.a.	Retrospective	24		Duolith SD1	Storz Medical	F	EM
33	Case series	n.a.	Prospective	260		Duolith SD1	Storz Medical	F	EM
34	Cohort study	1	Retrospective	24		Renova	Direx	L	EM
35	Cohort study	1	Retrospective	52		Omnispec ED1000	Medispec	F	EH
36	RCT	1	Prospective	12		Duolith SD1	Storz Medical	F	EM
37	Case series	n.a.	Prospective	24		Duolith SD1	Storz Medical	F	EM
38	Cohort study	1	Prospective	12		Omnispec ED1000	Medispec	F	EH
39	RCT	1	Prospective	24		Duolith SD1	Storz Medical	F	EM
40	Case series	n.a.	Prospective	7		Duolith SD1	Storz Medical	F	EM
41	RCT	1	Prospective	24		Intellect <sup>11</sup>	Chattanooga	F	EM
42	Case series	n.a.	Retrospective	24	52	Duolith SD1	Storz Medical	F	EM
43	RCT	1	Prospective	24		Renova	Direx	L	EM
44	RCT	1	Prospective	16		Renova	Direx	L	EM
45	Cohort study	1	Not specified	18		Not specified	Electronica Pagani	F/U	n.s.
46	Case series	n.a.	Prospective	8		Renova	Direx	L	EM
47	RCT	3	Prospective	24		Aries 2	Dornier	F	EM

<sup>9</sup> This is a retrospective analysis of patients who were treated with the same LI-ESWT protocol, with essential information (device used not specified). The authors divided their sample into two subsamples according to different IIEF-EF scores at baseline. Here this study is considered a case series without control group.

<sup>10</sup> Shenzhen Hyde Medical Equipment

<sup>11</sup> Intellect Focus Shockwave Therapy SKU

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Ref	V9	V10	V11	V12	V13	V14	V15	V16	V17
48	RCT	1	Prospective	n.s.		Well Wave	Richard Wolf	F	PE
49	Case series	n.a.	Prospective	10		Piezowave 2 linear	Richard Wolf	L	PE
50	Cohort study	2	Not specified	24		Omnispec ED1000	Medispec	F	EH
51	RCT	1	Prospective	7		MT 2000H	Urontech	F	EM
52	RCT	1	Prospective	24		MoreNova	Direx	L	EM
53	Cohort study	1	Retrospective	31		Omnispec ED1000	Medispec	F	EH
54	Case series	n.a.	Not specified	16		HB-ESWT-01	ZHME <sup>12</sup>	F	n.s.
55	Cohort study	1	Retrospective	12		UroGold 100	MTS	F	EH
56	RCT	1	Prospective	24		Duolith SD1	Storz Medical	F	EM
57	Case series	n.a.	Not specified	12	260	Duolith SD1	Storz Medical	F	EM
58	Case series	n.a.	Prospective	24	76	Aries 2	Dornier	F	EM
59	RCT	1	Prospective	12		Piezowave 2 linear	Richard Wolf	L	PE
60	Case series	n.a.	Prospective	18		Omnispec ED1000	Medispec	F	EH
61	Case series	n.a.	Prospective	24		Piezowave 2 linear	Richard Wolf	L	PE
62	RCT	1	Prospective	12		Swiss DolorClast	EMS	R	R
63	Case series	n.a.	Prospective	18		Piezowave 2 linear	Richard Wolf	L	PE
64	RCT	1	Prospective	24	52	Piezowave 2 linear	Richard Wolf	L	PE
65	RCT	1	Prospective	24		Aries 2	Dornier	F	EM
66	Case series	n.a.	Prospective	24	108	Not specified	Unknown	n.s.	n.s.
67	RCT	2	Prospective	24	36	Aries 2	Dornier	F	EM
68	Case series	n.a.	Retrospective	36		Duolith SD1	Storz Medical	F	EM
69	RCT	1	Prospective	9		Piezowave 2 linear	Richard Wolf	L	PE
70	RCT	1	Prospective	24	52	Omnispec ED1000	Medispec	F	EH
71	Case series	n.a.	Prospective	24		Duolith SD1	Storz Medical	F	EM
72	Case series	n.a.	Prospective	24		Renova	Direx	L	EM
73	Case series	n.a.	Not specified	10		Duolith SD1	Storz Medical	F	EM
74	Case series	n.a.	Prospective	24		Omnispec ED1000	Medispec	F	EH
75	RCT	1	Prospective	13		Omnispec ED1000	Medispec	F	EH
76	Case series	n.a.	Prospective	24		Renova	Direx	L	EM
77	Case series	n.a.	Prospective	20		Duolith SD1	Storz Medical	F	EM
78	RCT	1	Prospective	5		Duolith SD1	Storz Medical	F	EM
79	Case series	n.a.	Not specified	8		Renova	Direx	L	EM
80	Case series	n.a.	Prospective	24		Renova	Direx	L	EM
81	Case series	n.a.	Not specified	12		Renova	Direx	L	EM
82	RCT	1	Prospective	13		Omnispec ED1000	Medispec	F	EH
83	RCT	1	Prospective	13		Omnispec ED1000	Medispec	F	EH
84	Case series	n.a.	Prospective	13		Not specified	Unknown	n.s.	n.s.
85	RCT	1	Prospective	24		Duolith SD1	Storz Medical	F	EM
86	RCT	1	Prospective	13		Omnispec ED1000	Medispec	F	EH
87	Case series	n.a.	Not specified	24		Omnispec ED1000	Medispec	F	EH

<sup>12</sup> Zhanjiang Haibin Medical Equipment Co

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Ref	V18	V19	V20 <sup>13</sup>	V20 <sup>14</sup>	V20 <sup>15</sup>	V20 <sup>16</sup>	V21 <sup>13</sup>	V21 <sup>14</sup>	V21 <sup>15</sup>	V21 <sup>17</sup>
1	36	0	56.1		7.3					>6
2	34	0	59		8.6		94		75	
3	116	0	47.3			19-71				<6
4	113	0		50			n.s.			
5	34	0	35.3			25-50	23.4			6-84
6	126	0	50.5		12.4					>6
7	44	1	59.5		6.9		n.a.			
8	31	0	44.6			25-78				>6
9	56	15	62				n.a.			
10	17	0	67				n.s.			
11	16	<sup>18</sup>	63			52-72	n.a.			
12	76	0	52.8		11.7		n.s.			
13	26	0	43.8		8.1		n.s.			
14	21	3	56.3		9.1		>12			
15	51	9	33.9		6.2		24			12-36
16	5	0	31.2			24-36	n.s.			
17	50	0	41.9		11.7		n.s.			
18	63	0	57.1		5.1		25		5.5	
19	50	9	50.5		13.7					>3
20	41	0	51.6		11.8		54.5		33	
21	35	1		54				68		
22	20	4	58.3		4.9			7		3-18
23	25	0		56				44		
24	50	0		59				48		
25	27	0		61				24		
26	40	3	47.7		12.8		5.5		6.6	
27	30	0	52.8		7.9		n.s.			
28	35	2	48.3		3.5		45.3		25.1	
29	25	0	43.8			28-62	66			12-180
30	425	0		55		30-70	25			12-38
31	30	8	53.7		8					>6
32	111	0	53.7		11.6		n.s.			
33	30	0	55.8			42-68	21.8			6-60
34	91	0	46.9		11.9		48		32	
35	34	0	59.2			51-70	n.a.		--	
36	20	0	60.8		6.8		11.2		4.5	
37	19	8	57.4			38-70	46.3			12-120
38	60	14	33.4		6.2		24			12-36
39	44	25	42.3		9.9		33.7		36.5	
40	109	3	57.9			21-78	33.3			3-103
41	21	0	48.6		5.5		118		13	
42	69	0		55		45-66		12		6-36
43	40	0		60		54-66		36		24-72
44	46	10	64.6		5.3		n.a.			
45	20	0	45.6				n.s.			

<sup>13</sup> Mean

<sup>14</sup> Median

<sup>15</sup> Standard deviation

<sup>16</sup> Range

<sup>17</sup> Minimum value or range

<sup>18</sup> Approximately 25% of the patients were lost to follow-up. However, group-specific patients lost to follow-up were not reported.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Ref	V18	V19	V20 <sup>13</sup>	V20 <sup>14</sup>	V20 <sup>15</sup>	V20 <sup>16</sup>	V21 <sup>13</sup>	V21 <sup>14</sup>	V21 <sup>15</sup>	V21 <sup>17</sup>
46	35	0	33			21-68				>6
47	24	1	58.7		9.5					>6
48	20	0	59.2		8.7		n.s.			
49	25	3		60		55-69		60		18-222
50	5	<sup>19</sup>	62.2		2.7		n.a.			
51	46	8	63.2		5.4					>6
52	45	5	53.2			30-78				>6
53	78	0	56		9.6		n.s.			
54	45	0		60		30-84		38		6-120
55	24	0		61		48-70		61		36-61
56	22	0	51			45-60	n.s.			
57	18	0	61.1		7.2					>12
58	55	3	51			23-74	34.5			9-60
59	30	0	53.9		9.3		42			6-204
60	20	0	58.5		10.3		98.4		80.4	
61	12	0	35.5		7.1					>6
62	10	0	55.1			47-60	22.7		9.2	
63	25	0		61		27-73	24			
64	63	11	65.4		7.9					>6
65	21	3	57.5		10					>3
66	156	0	59.1		10.1		64.6		49	
67	49	7	52.9		7.2		n.a.			
68	710	298		58		24-83				>3
69	63	3		65.4	7.9					>6
70	30	0		53		31-72		66		12-240
71	52	0	60.1		11.5		38.3		26.9	
72	25	5	64.8			48-82	70.5		n.s.	
73	18	3		62		51-70		24		12-54
74	56	0		64		27-83		36		6-216
75	40	3		60		28-27		60		11-240
76	25	0		63		46-78		42		12-132
77	30	0	55.8			42-68	21.8			6-60
78	51	15		59		41-80		57		9-240
79	15	0		59.6		45-70	n.s.			
80	58	0	56.8			33-84				>3
81	31	0	59.9		12.2					>6
82	95	35	n.s.							>6
83	36	6	58.9		7.6		78		34	
84	33	4	61.3			41-79		60	n.s.	
85	50	0	55.5			32-75	8.8			6-12
86	46	6		58		27-72		42		6-240
87	20	0	56.1			33-73	34.7		n.s.	

<sup>19</sup> Approximately 40% of the patients were lost to follow-up. However, group-specific patients lost to follow-up were not reported.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Ref	V22	V23	V24	V25	V26	V27	V28	V29	V30
1	6	W1-W3 (2)	6 x 500	n.s.	0.25		No	No	n.s.
2	12	W1-W6 (2)	2 x 2000 + 1 x 1000	n.s.	0.096		No	No	5
3	6	W1-W3 (2)	5 x 300	n.s.	0.09		No	No	2.66
4	8	W1-W8 (1)	5 x 300	n.s.	n.s.		No	No	n.s.
5	8	W1-W8 (1)	4 x 1500	n.s.		90-120 mJ <sup>20</sup>	No	No	12
6	12	W2-W2 (3) and W5-W6 (3)	3 x 500	n.s.	0.1		No	No	5
7	6	W1-W6 (1)	8 x 1250	n.s.		90 mJ <sup>20</sup>	No	No	15
8	8	W1-W3 (2 - 3)	5 x 600	n.s.		1.2-2 bar <sup>21</sup>	No	No	7-12
9	6	D4, D5, D6, D7, W2, W4 post-OP	5 x 300	n.s.	0.09		No	No	2
10	6	W1-W3 (2)	2 x 1000 + 2 x 500	n.s.	0.1		No	No	5
11	12	W1-W2 (3) and W3-W8 (1)	5 x 300	n.s.	0.09		No	No	2
12	6	W1-W3 and W7-W9 (1)	3 x 1000	n.s.	0.09		No	No	5
13	6	W1-W6 (1)	2 x 1600 + 2 x 900	n.s.	0.09		No	No	n.s.
14	6	W1-W6 (1)	5 x 300	n.s.	0.09		No	No	8
15	12	W1-W2 (3) and W7-W9 (2)	5 x 300	n.s.	0.09		No	No	2
16	8	D45 (1) and D52-D58 (1)	2 x 1500	n.s.	0.25		No	No	n.s.
17	10	W1-W5 (2)	3000 (perineum)	n.s.	0.25		No	No	5
18	12	W1-W2 (3) and W7-W9 (2)	10 x 500	n.s.	0.15		No	No	2
19	6	W1-W6 (1)	6 x 500	n.s.	0.25		No	No	4
20	10	W1-W5 (1) and W25-W30 (1)	2 x 1800	n.s.	0.09		No	No	n.s.
21	12	W1-W6 (2)	2 x 2000 + 1 x 1000	n.s.	0.096		No	No	5
22	4	W1-W4 (1)	2 x 2000	n.s.	0.16		No	No	8
23	6	W1-W3 (2)	2 x 2000 + 1 x 1000	n.s.	0.096		No	No	5
24	6	W1-W6 (1)	1 x 2000 + 1 x 1000	n.s.	0.2-0.25		No	No	n.s.
25	4	W1-W4 (1)	2 x 2000	n.s.	n.s.		No	No	8
26	6	W1-W6 (1)	1 x 4000	n.s.		2.4 bar <sup>21</sup>	No	No	17
27	6	W1, W3, W5 (2)	2 x 1000 + 2 x 500	n.s.	0.25		No	No	3
28	12	W1-W3 and W7-W9 (1)	6 x 300 to 400	n.s.		7.5 KV <sup>22</sup>	No	No	1.66
29	6	W1-W3 (2)	2 x 3000	n.s.	n.s.		No	No	n.s.
30	6	W1-W6 (1)	5 x 1200	n.s.	0.2		No	No	8
31	12	W1-W2 (3) and W7-W9 (2)	5 x 300	n.s.	n.s.		No	No	n.s.
32	6	W1-W6 (1)	8 x 300	n.s.	0.12		No	No	3
33	12	W1-W6 (2)	2 x 1000 + 2 x 500	n.s.	0.25		No	No	6
34	5	W1-W5 (1)	2 x 1800	n.s.	0.09		No	No	n.s.
35	12	W1-W6 (2)	5 x 300	n.s.	0.09		No	No	2.66
36	5	W1-W5 (1)	6 x 500	n.s.	0.15		No	No	5
37	6 <sup>23</sup>	W1-W6 (1 or 2)	Not specified	n.s.	n.s.		No	No	n.s.
38	12	W1-W3 and W7-W9 (1)	5 x 300	n.s.	0.09		No	No	2

<sup>20</sup> Energy that is used to electromagnetically accelerate the bullet in certain radial ESWT devices (c.f. Figure 2D in the main text).

<sup>21</sup> Air pressure that is used to accelerate the bullet in pneumatic, radial ESWT devices (c.f. Figure 2D in the main text).

<sup>22</sup> Current that is rapidly discharged across two electrode tips (spark-gap) to vaporize the surrounding water in electrohydraulic ESWT devices (c.f. Figure 2A in the main text).

<sup>23</sup> 14 patients treated with 12 treatment sessions and 5 patients treated with 6 treatment session; all patients were combined to a single group.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Ref	V22	V23	V24	V25	V26	V27	V28	V29	V30
39	4	W1-W4 (1)	10 x 300	n.s.	0.2		No	No	5
40	6	W1-W3 (2)	2 x 1000 + 2 x 500	n.s.	0.25		No	No	4-6
41	12	W1-W3 (2) and W7-W9 (2)	5 x 600	n.s.	0.09		No	No	n.s.
42	12	W1-W12 (1)	6 x 500	n.s.	0.2		No	No	4
43	4	W1-W4 (1)	2 x 1600 + 2 x 900	n.s.	0.09		No	No	2
44	8	W1-W8 (1)	4 x 600	n.s.	0.09		No	No	5
45	12	W1-W3 and W7-W9 (1)	6 x 300	n.s.	0.15		No	No	n.s.
46	4	W1-W4 (1)	2 x 1600 + 2 x 900	n.s.	0.09		No	No	5
47	12	W1-W6 (2)	4 x 1000	n.s.	0.05		No	No	8
48	7	W1-W3 (2 to 3)	1 x 1500	n.s.	n.s.		No	No	4
49	6	W1-W6 (1)	2 x 3300	n.s.	0.16		No	No	n.s.
50	12	W1-W2 (3) and W3-W8 (1)	5 x 300	n.s.	0.09		No	No	2
51	12	W1-W3 and W7-W9 (1)	3 x 1000	n.s.	<b>24</b>		No	No	5
52	5	D1-D5 (1 per day)	2 x 360	n.s.	n.s.		No	No	n.s.
53	6	W1-W3 (2)	1500 - 2400	n.s.	0.09		No	No	2
54	8	W1-W4 (2)	4 x 1600 + 3 x 1200	n.s.	0.05		No	No	3.33
55	6	W1-W6 (1)	1 x 3000	n.s.	0.09		No	No	n.s.
56	12	W1-W6 (2)	1 x 3000	n.s.	0.25		No	No	3
57	4	W1-W4 (1)	5 x 600	n.s.	0.15		No	No	5
58	12	W1-W3 and W7-W9 (1)	5 x 300	n.s.	0.009		No	No	n.s.
59	4	W1-W2 (2)	2 x 3000	n.s.	0.16		No	No	n.s.
60	<b>6<sup>25</sup></b>	W1-W3 (2)	5 x 300	n.s.	0.09		No	No	2
61	6	W1-W6 (1)	2 x 1000	n.s.	0.16		No	No	n.s.
62	6	W1-W3 (2)	1 x 2000	n.s.	0.09		No	No	n.s.
63	6	W1-W6 (1)	2 x 2000	n.s.	0.16		No	No	n.s.
64	10	W1-W5 (1) and W10-W14 (1)	1 x 600	n.s.	0.09		No	No	5
65	18	W1-W6 (1) and W25-W30 (2)	4 x 1000 + 2 x 500	n.s.	0.05		No	No	8
66	12	W1-W3 and W7-W9 (1)	5 x 300	n.s.	0.09		No	No	2
67	12	W1-W3 and W7-W9 (1)	5 x 300	n.s.	0.09		No	No	2
68	5	W1-W5 (1)	6 x 500	n.s.	0.1		No	No	n.s.
69	10	W1-W5 (1) and W10-W14 (1)	1 x 600	n.s.	0.09		No	No	5
70	12	W1-W3 and W7-W9 (1)	5 x 300	n.s.	0.09		No	No	2.66
71	12	W1-W12 (1)	6 x 500	n.s.	0.15		No	No	4
72	4	W1-W4 (1)	4 x 900	n.s.	0.09		No	No	n.s.
73	6	W1-W6 (1)	3 x 1000	n.s.	<b>24</b>		No	No	5
74	12	W1-W3 and W7-W9 (1)	5 x 300	n.s.	0.09		No	No	2
75	12	W1-W3 and W7-W9 (1)	5 x 300	n.s.	0.09		No	No	2
76	4	W1-W4 (1)	2 x 1600 + 2 x 900	n.s.	0.09		No	No	n.s.
77	12	W1 (2) to W6 (2)	2 x 1000 + 2 x 500	n.s.	0.25		No	No	6
78	5	W1-W5 (1)	6 x 500	n.s.	0.15		No	No	5
79	4	W1-W4 (1)	2x 1600 + 2 x 900	n.s.	0.09		No	No	5
80	4	W1-W4 (1)	4 x 900	n.s.	0.09		No	No	5
81	4	W1-W4 (1)	4 x 900	n.s.	0.09		No	No	n.s.
82	12	W1-W3 and W7-W9 (1)	5 x 300	n.s.	0.09		No	No	2
83	12	W1-W3 and W7-W9 (1)	5 x 300	n.s.	0.09		No	No	2
84	12	W1-W3 and W7-W9 (1)	5 x 300	n.s.	0.09		No	No	2
85	4	W1-W4 (1)	2000	n.s.	0.25		No	No	4

<sup>24</sup> 20 mJ/mm<sup>2</sup>, 15 mJ/mm<sup>2</sup> and 12mJ/mm<sup>2</sup> (these values are most probably incorrect; details in the Discussion section of the main text.

<sup>25</sup> Non-responders received a second series of 6 treatment sessions (W7-W9 (2)); all patients were combined to a single group.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Ref	V22	V23	V24	V25	V26	V27	V28	V29	V30
86	12	W1-W3 and W7-W9 (1)	5 x 300	n.s.	0.09		No	No	2
87	12	W1-W3 and W7-W9 (1)	5 x 300	n.s.	0.09		No	No	2

Ref	V31
1	PDE5i (20 mg of tadalafil every second day)
2	PDE5i (daily from W1-W4)
3	PDE5i (daily for 6 months)
4	--
5	PDE5i + L-arginine
6	PDE5i (daily for 2 months)
7	--
8	--
9	PDE5i (daily for 6 months post-OP)
10	--
11	--
12	--
13	--
14	PDE5i (daily starting at W11)
15	---
16	--
17	--
18	PDE5i (daily)
19	PDE5i + L-arginine
20	--
21	--
22	--
23	PDE5i (daily from W1-W4)
24	--
25	--
26	2000 shots into bilateral ischiocavernosus and bulbospongiosus muscles
27	--
28	Vacuum erectile device (3x /week; 9 weeks)
29	--
30	--
31	--
32	--
33	--
34	PRP (3x, W1, W3, W5)
35	PDE5i (daily)
36	--
37	--
38	--
39	--
40	--
41	Kegel exercises three times daily for 6 weeks
42	--
43	--
44	PDE5i (daily for 8 weeks post-OP)
45	--
46	--
47	--
48	TMS
49	--

---

<b>Ref</b>	<b>V31</b>
50	--
51	--
52	--
53	PDE5i (daily for 12 weeks)
54	PDE5i (daily or on demand)
55	PDE5i (on demand)
56	Chorionic gonadotropin + extract of Epimedium Breviconum
57	--
58	--
59	--
60	PDE5i (daily or on demand)
61	PDE5i (daily for 6 months post-accident)
62	--
63	PDE5i (daily for 6 weeks)
64	--
65	--
66	--
67	--
68	--
69	--
70	--
71	PDE5i (daily for 12 weeks or on demand)
72	PDE5i (daily for 4 weeks)
73	--
74	--
75	---
76	--
77	--
78	--
79	--
80	--
81	--
82	--
83	--
84	--
85	PDE5i (daily for 4 weeks)
86	--
87	--

---

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Ref	V32	V33	V34 <sup>26</sup>	V34 <sup>27</sup>	V34 <sup>28</sup>	V34 <sup>29</sup>	V35 <sup>26</sup>	V35 <sup>27</sup>	V35 <sup>28</sup>	V35 <sup>30</sup>	V36
1	42	0	57.5		6.9		51.2		8.4		ESWT (6 sessions; W1-W3 (2)) + 5 mg of tadalafil daily
2	17	0	58.4			7	65		48		Sham ESWT + PDE5i (daily from W1-W4)
5	34	0	35.3				25-50	23.4		6-84	PDE5i + L-arginine
7	62	32	62.5		7.6		--		--		Standard care
9	59	20		66			--		--		PDE5i (daily for 6 months post-OP)
10	16	1		64.4			n.s.				Sham ESWT
11	13	<sup>31</sup>		61			49-69	--	--		PDE5i (2x per week for >4 weeks)
12	484	0	52.5		11.6		n.s.				ESWT (Renova/Direx; W1-W4 (1); 3600 shots, 0,09 mJ/mm <sup>2</sup> , 5 Hz)
15	44	14	31.2		5.2		12			11-24	PDE5i on demand
19	50	8	49.6		14					>3	ESWT (6 sessions; W1-W6 (1))
21	35	2		61				48			Sham ESWT
22	20	4	60		5		7			3-18	Sham ESWT
23	25	0		58				56			ESWT (same protocol) + placebo PDE5i (daily from W1-W4)
25	24	0		55			n.s.				Sham ESWT
26	40	1	48.5		11.2		4.7		4.6		Sham ESWT
28	35	2	46.7		4.9		43.9		27.2		ESWT (same protocol)
29	26	1	47.1			32-63	91			24-180	PDE5i on demand
34	93	0	51.2		11.4		48		36		ESWT (5x; W1-W5 (1))
35	32	0	58.4			49-70	--		--		PDE5i (daily)
36	18	0	64.3		4.8		14.3		16.4		Sham ESWT
38	40	8	30.7		4.2		15			6-24	PDE5i on demand
39	22	22	39.9		11.6		37.2		46.3		Sham ESWT
41	21	0	47.5		5.7					>6	Kegel exercises three times daily for 6 weeks
43	40	4		60		53-64		54		36-72	Sham ESWT
44	46	5	64.4		5.3		--		--		PDE5i (daily for 8 weeks post-OP)
45	20	0	44.3		n.s.		n.s.				fESWT (W1-W3 and W7-W9 (1))
47	24	2	57.7		9.3					>6	ESWT (W1-W4 (3), EFD = 0.05 mJ/mm <sup>2</sup> , 8 Hz)
48	20	0	59.2		8.7		n.s.				Only ESWT (same protocol; no TMS)

<sup>26</sup> Mean

<sup>27</sup> Median

<sup>28</sup> Standard deviation

<sup>29</sup> Range

<sup>30</sup> Minimum value or range

<sup>31</sup> Approximately 25% of the patients were lost to follow-up. However, group-specific patients lost to follow-up were not reported.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Ref	V32	V33	V34 <sup>26</sup>	V34 <sup>27</sup>	V34 <sup>28</sup>	V34 <sup>29</sup>	V35 <sup>26</sup>	V35 <sup>27</sup>	V35 <sup>28</sup>	V35 <sup>30</sup>	V36
50	11	<sup>32</sup>	62.9		1.8		--		--		ESWT (12x; W1-W3 and W7-W9 (2))
51	49	6	65.1		7.9					>6	Sham ESWT
52	42	2	50.5			30-78				>6	ESWT (W1-W2 (3), 600 ESWs each, not further specified)
53	78	0	58.2		3.2		n.s.				PDE5i (daily for 12 weeks)
55	24	0		61		54-69		68		12-96	Radial ESWT (Zimmer enPulse, W1-W6 (1), 10.000 rESWs, 15 Hz, 90 mJ)
56	20	0	51			45-60	n.s.				Chorionic gonadotropin + ICA (no ESWT)
59	30	0	54.7		9.2		45			6-204	Sham ESWT
62	10	0	52.2			46-61	32.8		23.7		Sham ESWT
64	63	20	63.3		9.5					>6	Sham ESWT
65	22	4	55.6		9					>3	ESWT (W1-W6 (2) and W25-W30 (1))
67	53	10	51.2		6.3		--		--		Sham ESWT
69	63	3	63.3		9.5					>6	Sham ESWT
70	16	0	55.1			38-72	66			12-180	Sham ESWT
75	18	0		64		29-81	72			8-180	Sham ESWT
78	54	14		60		37-79		64		12-240	Sham ESWT
82	40	23	n.s.				n.s.				Sham ESWT
83	34	6	63.3		6.4		89		52		Sham ESWT
85	50	0	54			29-71	9			7-12	ESWT (same protocol)
86	21	1		57		35-77		60		6-240	Sham ESWT

Ref	V37	V38	V39 <sup>26</sup>	V39 <sup>27</sup>	V39 <sup>28</sup>	V39 <sup>29</sup>	V40 <sup>26</sup>	V40 <sup>27</sup>	V40 <sup>28</sup>	V40 <sup>30</sup>	V41
1	27	0	54.1		6.5					>6	ESWT (6 sessions; W1-W3 (2))
5	34	0	35.3			25-50	23.4			6-84	PDE5i
11	139	<sup>31</sup>		66		46-75	--	--			No treatment
28	35	1	47.9		5.7		45.5	22			Vacuum erectile device (same protocol)
47	24	1	56.5		7.6					>6	ESWT (W1-W6 (2), EFD = 0,1 mJ/mm <sup>2</sup> , 5 Hz)
50	178	<sup>32</sup>	66.6		0.45		--	--			None

<sup>32</sup> Approximately 40% of the patients were lost to follow-up. However, group-specific patients lost to follow-up were not reported.

It is made available under a [CC-BY 4.0 International license](#) .

---

Ref	V42	V43	V44 <sup>26</sup>	V44 <sup>27</sup>	V44 <sup>28</sup>	V44 <sup>29</sup>	V45 <sup>26</sup>	V45 <sup>27</sup>	V45 <sup>28</sup>	V45 <sup>30</sup>	V46
47	25	4	57.6	6.9						>6	ESWT (W1-W4 (3), EFD = 0,1 mJ/mm <sup>2</sup> , 5 Hz)

---

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Ref	V47	V48	V49	V50	V51	V52 <sup>33</sup>	V52 <sup>34</sup>	V52 <sup>35</sup>	V52 <sup>36</sup>	V53	V54	V55
1	Yes	No	n.a.	n.a.	No					No	Yes	
2	Yes	No	n.a.	n.a.	No	7.7	1.3	12.9	2.1	Yes	Yes	A
3	Yes	No	n.a.	n.a.	No					n.a.	Yes	
4	Yes	No	n.a.	n.a.	No					n.a.	Yes	
5	Yes	No	n.a.	n.a.	No	14.7	1.5	25.8	3.6	Yes	Yes	B
6	Yes	No	n.a.	n.a.	No					n.a.	Yes	
7	No	Yes	No	n.a.	No					n.a.	n.a.	
8	Yes	No	n.a.	n.a.	No					n.a.	Yes	
9	No	Yes	No	n.a.	No					n.a.	n.a.	
10	No	Yes	No	n.a.	No					Yes	Yes	A
11	No	Yes	No	n.a.	No					n.a.	n.a.	
12	Yes	No	n.a.	n.a.	No					No	Yes	
13	Yes	No	n.a.	n.a.	No					n.a.	Yes	
14	No	Yes	No	n.a.	No	14.3	5.2	20.3	8.4	n.a.	Yes	
15	No	Yes	No	n.a.	No	8.6	3.6	16.3	5.5	No	Yes	C
16	Yes	No	n.a.	n.a.	No					n.a.	Yes	
17	Yes	No	n.a.	n.a.	No					n.a.	Yes	
18	Yes	No	n.a.	n.a.	No					n.a.	No	B
19	No	Yes	No	n.a.	No	16.5	4.1	21.5	4.5	No	Yes	
20	Yes	No	n.a.	n.a.	No	15.17	3.75	21.61	3.6	n.a.	Yes	
21	No	Yes	No	n.a.	No	14	1.7	20	2.4	Yes	Yes	B
22	No	Yes	No	n.a.	No					Yes	n.a.	C
23	Yes	No	n.a.	n.a.	No	21.2	2.5	25.3	2.3	No	Yes	
24	Yes	No	n.a.	n.a.	No					n.a.	Yes	
25	Yes	No	n.a.	n.a.	No					Yes	Yes	A
26	Yes	Yes	Yes	BOCF	No	16.2	0.6	17	1.2	Yes	No	D
27	Yes	No	n.a.	n.a.	No					n.a.	Yes	
28	No	Yes	No	n.a.	No	13.3	1.6	18.9	--	No	Yes	A
29	No	Yes	No	n.a.	No					No	Yes	C
30	Yes	No	n.a.	n.a.	No					n.a.	Yes	
31	No	Yes	No	n.a.	No					n.a.	Yes	
32	Yes	No	n.a.	n.a.	No					n.a.	Yes	
33	Yes	No	n.a.	n.a.	No					n.a.	No	
34	Yes	No	n.a.	n.a.	No	14.3	4.4	23.8	4.4	No	Yes	
35	Yes	No	n.a.	n.a.	No					Yes	n.a.	A
36	Yes	No	n.a.	n.a.	No					Yes	n.a.	A
37	No	Yes	No	n.a.	No					n.a.	Yes	
38	No	Yes	No	n.a.	No					No	Yes	C
39	Yes	Yes	Yes	BOCF	No	20.32	2.32	23.1	2.82	No	Yes	A
40	No	Yes	No	n.a.	No	13.5	4.6	22.1	5.3	n.a.	Yes	
41	Yes	No	n.a.	n.a.	No	12.8	3.2	17.5	2.7	Yes	Yes	A
42	Yes	No	n.a.	n.a.	No					n.a.	Yes	
43	No	Yes	No	n.a.	No	12	8-17 <sup>37</sup>	15	7-22 <sup>37</sup>	No	Yes	A
44	No	Yes	No	n.a.	No					n.a.	n.a.	
45	Yes	No	n.a.	n.a.	No					No	Yes	
46	Yes	No	n.a.	n.a.	No					n.a.	Yes	
47	No	Yes	No	n.a.	No	18.3	4.2	23.6	4	No	Yes	

<sup>33</sup> Mean LLEF-EF score at baseline

<sup>34</sup> Standard deviation of the LLEF-EF score at baseline

<sup>35</sup> Mean LLEF-EF score at follow-up

<sup>36</sup> Standard deviation of the LLEF-EF score at follow-up

<sup>37</sup> Range

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Ref	V47	V48	V49	V50	V51	V52 <sup>33</sup>	V52 <sup>34</sup>	V52 <sup>35</sup>	V52 <sup>36</sup>	V53	V54	V55
48	Yes	No	No	n.a.	No					No	Yes	
49	No	Yes	No	n.a.	No					n.a.	Yes	
50	No	Yes	No	n.a.	No					n.a.	n.a.	
51	No	Yes	No	n.a.	No	16.6	3	21.7	3	Yes	Yes	A
52	No	Yes	No	n.a.	No	18.1	17.1-19.1 <sup>38</sup>	21	19.4-22.6 <sup>38</sup>	No	Yes	
53	Yes	No	n.a.	n.a.	No					Yes	Yes	B
54	Yes	No	n.a.	n.a.	No					n.a.	Yes	
55	Yes	No	n.a.	n.a.	No					No	Yes	
56	Yes	No	n.a.	n.a.	No					No	Yes	
57	Yes	No	n.a.	n.a.	No					n.a.	Yes	
58	No	Yes	No	n.a.	No					n.a.	Yes	
59	Yes	No	n.a.	n.a.	No					Yes	Yes	A
60	Yes	No	n.a.	n.a.	No					n.a.	Yes	
61	Yes	No	n.a.	n.a.	No					n.a.	Yes	
62	Yes	No	n.a.	n.a.	No					Yes	Yes	A
63	Yes	No	n.a.	n.a.	No					n.a.	Yes	
64	No <sup>39</sup>	Yes	No	n.a.	No	11.2	6.6	16	9.8	No	Yes	
65	No	Yes	No	n.a.	No	16.2	3.8	19.3	4	No	Yes	
66	Yes	No	n.a.	n.a.	No					n.a.	Yes	
67	No	Yes	No	n.a.	No					n.a.	n.a.	
68	No	Yes	No	n.a.	No					n.a.	Yes	
69	No	Yes	No	n.a.	No	10.9	9.1-12.7 <sup>38</sup>	13.1	9.3-13.4 <sup>38</sup>	Yes	No	D
70	Yes	No	n.a.	n.a.	No	13.8	3.6	19	3.3	Yes	Yes	A
71	Yes	No	n.a.	n.a.	No					n.a.	Yes	
72	No	Yes	No	n.a.	No					n.a.	Yes	
73	No	Yes	No	n.a.	Yes <sup>40</sup>					n.a.	n.a.	
74	Yes	No	n.a.	n.a.	No					n.a.	Yes	
75	No	Yes	No	n.a.	No	7	6-10 <sup>37</sup>	13	9-18 <sup>37</sup>	No	Yes	A
76	Yes	No	n.a.	n.a.	No	14.9	--	19.9	--	n.a.	Yes	
77	Yes	No	n.a.	n.a.	No					n.a.	No	
78	No	Yes	No	n.a.	No					No	No	
79	Yes	No	n.a.	n.a.	No	15	--	20	--	n.a.	Yes	
80	Yes	No	n.a.	n.a.	No	14.8	4.8	22.3	--	n.a.	Yes	
81	Yes	No	n.a.	n.a.	No	16.5	6.4	21	6.4	n.a.	Yes	
82	No	Yes	No	n.a.	No	9.5	2	22	3	Yes	Yes	A
83	No	Yes	No	n.a.	No	10.2	3.8	17.8	4.8	Yes	Yes	C
84	No	Yes	No	n.a.	No	8.8	--	12.3	--	n.a.	Yes	
85	Yes	No	n.a.	n.a.	No	11.6		21.5		No	Yes	B
86	No	Yes	No	n.a.	No	11.5	0.8 <sup>6</sup>	18.2	0.8	Yes	Yes	B
87	Yes	No	n.a.	n.a.	No	13.5	4.1	20.9	5.8	n.a.	Yes	

<sup>38</sup> 95% confidence interval of the mean

<sup>39</sup> The authors stated that they performed a modified ITT analysis. To this end, patients who were found ineligible after randomization were excluded (i.e. patients who met all inclusion criteria but with a baseline IIEF-EF score > 25). However, an IIEF-EF score  $\geq 25$  was an exclusion criteria used in this trial, raising the question why patients were randomized into the trial despite the fact that they fulfilled one of the exclusion criteria and were therefore excluded after randomization. Furthermore, patients with missing primary outcome data were also excluded. However, this should be considered lack of missing data imputation rather than performing a modified ITT analysis.

<sup>40</sup> Patients with de novo use of erectogenic aids at the first follow-up were excluded from the analysis.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

## REFERENCES

1. İbis MA, Ozkaya F, Tokatli Z, Akpınar C, Yaman O. Efficacy of low-intensity shockwave therapy with different tadalafil regimens in patients with PDE5 inhibitor-resistant erectile dysfunction: a retrospective cohort study. *Int Urol Nephrol* 2024;56:407-413.
2. Kalyvianakis D, Mykoniatis I, Pyrgidis N, Kapoteli P, Zilotis F, Hatzichristou D. The effect of combination treatment with low-intensity shockwave therapy and daily tadalafil on severe erectile dysfunction: a double-blind, randomized, sham-controlled clinical trial. *J Sex Med* 2024;21:533-538.
3. Kaynak Y, Gruenwald I. Long-term effects of combination treatment comprising low-intensity extracorporeal shockwave therapy and tadalafil for patients with erectile dysfunction: a retrospective study. *Int J Impot Res* 2024;36:601-606.
4. Rubino M, Ricipito A, Finati M et al. Impact of low-intensity extracorporeal shockwave therapy on vascular parameters and sexual function in patients with arteriogenic erectile dysfunction. *Asian J Androl* 2024;26:344-348.
5. Trishch VI, Mysak AI, Trishch AI, Mandzii AP. Assessment of the treatment effectiveness of men with mild and medium degree of erectile dysfunction. *Pol Merkur Lekarski* 2024;52:79-86.
6. Bayraktar N. Non-invasive alternative for phosphodiesterase inhibitor-refractory erectile dysfunction: Real-life experience with low-intensity extracorporeal shockwave therapy. *Medicine (Baltimore)* 2023;102:e35939.
7. Bryk DJ, Murthy PB, Ericson KJ, Shoskes DA. Radial wave therapy does not improve early recovery of erectile function after nerve-sparing radical prostatectomy: a prospective trial. *Transl Androl Urol* 2023;12:209-216.
8. Islam R, Rahaman KS, Hawlader MDH. Efficacy of low-intensity extra corporal shockwave therapy (LI-ESWT) in patients with erectile dysfunction. *J Family Reprod Health* 2023;17:93-99.
9. Jang SW, Lee EH, Chun SY et al. Comparison of the efficacy of the early LI-SWT plus daily tadalafil with daily tadalafil only as penile rehabilitation for postprostatectomy erectile dysfunction. *Int J Impot Res* 2023;35:447-453.
10. Kennady EH, Bryk DJ, Ali MM et al. Low-intensity shockwave therapy improves baseline erectile function: a randomized sham-controlled crossover trial. *Sex Med* 2023;11:qfad053.
11. Kohada Y, Babasaki T, Goto K et al. Long-term efficacy of penile rehabilitation with low-intensity extracorporeal shock wave therapy for sexual and erectile function recovery following robotic-assisted radical prostatectomy: a single-cohort pilot study. *Sex Med* 2023;11:qfad023.
12. Kurosawa M, Tsujimura A, Morino J et al. Efficacy and patient satisfaction of low-intensity shockwave treatment for erectile dysfunction in a retrospective real-world study in Japan. *Int J Urol* 2023;30:375-380.
13. Ma MF, He JH, Zhao XD, et al. [Low-intensity extracorporeal shockwave therapy improves symptoms of erectile dysfunction: A preliminary study]. *Zhonghua Nan Ke Xue* 2023;29:239-243. Chinese.
14. Vena W, Vaccalluzzo L, LA Vignera S, et al. Low-intensity shockwave treatment (LISWT) improves penile rigidity in eugonadal subjects with erectile dysfunction: a pilot study. *Minerva Endocrinol (Torino)*. 2023;48:4-11.
15. Wang D, Wang SJ, Li YJ, et al. The treatment satisfaction in patients and their partners treated with low-intensity extracorporeal shock wave therapy and sildenafil: a prospective non-randomized controlled study. *Patient Prefer Adherence* 2023;17:583-589.
16. Cocci A, Fassio G, Migliorini F et al. Low-intensity extracorporeal shock wave therapy (Li-ESWT) for priapism-induced erectile dysfunction in young patients: the first case series. *Int J Impot Res*. 2022;34:277-279.
17. Daneshwar D, Nordin A. Low intensity extracorporeal shockwave therapy for chronic pelvic pain syndrome patients with erectile dysfunction. *Medicine (Baltimore)* 2022;101:e28546.
18. Ergün M, Akyüz O. Is Li-ESWT effective in diabetic patients with severe erectile dysfunction? *Asian J Androl* 2022;24:521-524.
19. Gallo L, Pecoraro S, Sarnacchiaro P. Adjuvant daily therapy with L-arginine 2,500 mg and tadalafil 5 mg increases efficacy and duration of benefits of low-intensity extracorporeal shock wave therapy for erectile dysfunction: A prospective, randomized, single-blinded study with 1-year follow-up. *Investig Clin Urol* 2022;63:83-91.
20. Geyik S. A single-centre result of two courses of low-intensity shockwave therapy (Li-SWT) in erectile dysfunction. *Andrologia* 2022;54:e14324.
21. Kalyvianakis D, Mykoniatis I, Pyrgidis N et al. The effect of low-intensity shock wave therapy on moderate erectile dysfunction: a double-blind, randomized, sham-controlled clinical trial. *J Urol* 2022;208:388-395.
22. Motil I, Macik D, Sramkova K, Jarkovsky J, Sramkova T. Linear low-intensity extracorporeal shockwave therapy as a method for penile rehabilitation in erectile dysfunction patients after radical prostatectomy: a randomized, single-blinded, sham-controlled clinical trial. *Urol Int* 2022;106:1050-1055.
23. Mykoniatis I, Pyrgidis N, Zilotis F et al. The effect of combination treatment with low-intensity shockwave therapy and tadalafil on mild and mild-to-moderate erectile dysfunction: a double-blind, randomized, placebo-controlled clinical trial. *J Sex Med* 2022;19:106-115.
24. Oginski N, Apel H, Richterstetter M et al. Analysis of the impact of clinical factors on low-intensity extracorporeal shockwave therapy for erectile dysfunction. *Urol Int* 2022;106:1041-1049.
25. Ong WLK, Lechmiannandan S, Lim YL, Manoharan D, Lee SB. Early outcomes of short-course low intensity shockwave therapy (LiSWT) for erectile dysfunction: A prospective, randomized, double-blinded, sham-controlled study in Malaysia. *Andrologia* 2022;54:e14518.
26. Sandoval-Salinas C, Saffon JP, Martínez JM, Corredor HA, Gallego A. Are radial pressure waves effective for the treatment of moderate or mild to moderate erectile dysfunction? A randomized sham therapy controlled clinical trial. *J Sex Med* 2022;19:738-744.
27. Scropo FI, Pezzoni F, Gaeta F et al. LI-ESWT improves hemodynamic parameters thus suggesting neoangiogenesis in patients with vascular erectile dysfunction. *Int J Impot Res* 2022;34:237-242.
28. Tao R, Chen J, Wang D, et al. The efficacy of Li-ESWT combined with ved in diabetic ed patients unresponsive to PDE5Is: a single-center, randomized clinical trial. *Front Endocrinol* 2022;13:937958.
29. Zanaty F, Badawy A, Kotb H, Elsarfy F, Salman B. Efficacy and safety of low-intensity extracorporeal shock wave therapy versus on-demand tadalafil for erectile dysfunction. *Arab J Urol* 2022;20:189-194.
30. Adeldaeim HM, Abouyoussef T, Gebaly OE et al. Prognostic indicators for successful low-intensity extracorporeal shock wave therapy treatment of erectile dysfunction. *Urology* 2021;149:133-139.
31. Akande TO, Akinwunmi OM, Adebayo SA, Akinyinka AO, Shittu OB. Efficacy and safety of low-intensity extracorporeal shockwave therapy for treatment of vascular erectile dysfunction in nigerian men: report of a study in ibadan, south-west nigeria. *Ann Ib Postgrad Med* 2021;19:8-14.
32. Caretta N, De Rocco Ponce M, Minicuci N et al. Efficacy of penile low-intensity shockwave treatment for erectile dysfunction: correlation with the severity of cavernous artery disease. *Asian J Androl* 2021;23:462-467.
33. Chung E, Cartmill R. Evaluation of long-term clinical outcomes and patient satisfaction rate following low intensity shock wave therapy

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

- in men with erectile dysfunction: a minimum 5-year follow-up on a prospective open-label single-arm clinical study. *Sex Med* 2021;9:100384.
34. Geyik S. Comparison of the efficacy of low-intensity shock wave therapy and its combination with platelet-rich plasma in patients with erectile dysfunction. *Andrologia* 2021;53:e14197.
  35. Karakose A, Yitgin Y. Penile rehabilitation with low-intensity extracorporeal shock wave therapy in patients after prostate cancer surgery. Early physiological changes and postoperative follow-up outcomes. *Int J Clin Pract* 2021;75:e14804.
  36. Ladegaard PBJ, Mortensen J, Skov-Jepesen SM, Lund L. Erectile dysfunction a prospective randomized placebo-controlled study evaluating the effect of low-intensity extracorporeal shockwave therapy (LI-ESWT) in men with erectile dysfunction following radical prostatectomy. *Sex Med* 2021;9:100338.
  37. Lau W, Shum CF, Lua HCA, Teo CPC. Low-intensity shockwave therapy in the management of erectile dysfunction in Singapore. *Ann Acad Med Singap* 2021;50:652-654.
  38. Lei Q, Wang D, Liu C, Ji Z, Yan S. Comparison of the efficacy and safety of low-intensity extracorporeal shock wave therapy versus on-demand sildenafil for erectile dysfunction. *Transl Androl Urol* 2021;10:860-868.
  39. Ortac M, Özmez A, Cilesiz NC, Demirelli E, Kadioğlu A. The impact of extracorporeal shock wave therapy for the treatment of young patients with vasculogenic mild erectile dysfunction: A prospective randomized single-blind, sham controlled study. *Andrology* 2021;9:1571-1578.
  40. Palmieri A, Arcaniolo D, Palumbo F et al. Low intensity shockwave therapy in combination with phosphodiesterase-5 inhibitors is an effective and safe treatment option in patients with vasculogenic ED who are PDE5i non-responders: a multicenter single-arm clinical trial. *Int J Impot Res* 2021;33:634-640.
  41. Shendy WS, Elsoghier OM, El Semary MM et al. Effect of low-intensity extracorporeal shock wave therapy on diabetic erectile dysfunction: Randomised control trial. *Andrologia* 2021;53:e13997.
  42. Tzou KY, Hu SW, Bamodu OA, Wang YH, Wu WL, Wu CC. Efficacy of penile low-intensity shockwave therapy and determinants of treatment response in taiwanese patients with erectile dysfunction. *Biomedicines* 2021;9:1670.
  43. Vinay J, Moreno D, Rajmil O, Ruiz-Castañe E, Sanchez-Curbelo J. Penile low intensity shock wave treatment for PDE5I refractory erectile dysfunction: a randomized double-blind sham-controlled clinical trial. *World J Urol* 2021;39:2217-2222.
  44. Baccaglini W, Pazeto CL, Corrêa Barros EA, et al. The role of the low-intensity extracorporeal shockwave therapy on penile rehabilitation after radical prostatectomy: a randomized clinical trial. *J Sex Med* 2020;17:688-694.
  45. Eryilmaz R, Kaplan Ş, Aslan R, Demir M, Taken K. Comparison of focused and unfocused ESWT in treatment of erectile dysfunction. *Aging Male* 2020;23:206-209.
  46. Huang YP, Liu W, Liu YD, Zhang M, Xu SR, Lu MJ. Effect of low-intensity extracorporeal shockwave therapy on nocturnal penile tumescence and rigidity and penile haemodynamics. *Andrologia* 2020;52:e13745.
  47. Kalyvianakis D, Mykoniatis I, Memmos E, Kapoteli P, Memmos D, Hatzichristou D. Low-intensity shockwave therapy (LiST) for erectile dysfunction: a randomized clinical trial assessing the impact of energy flux density (EFD) and frequency of sessions. *Int J Impot Res* 2020;32:329-337.
  48. Konchugova TV, Kulchitskaya DB, Kiyatkin VA, Gushchina NV. [Transcerebral magnetic and shock wave therapy in correction of erectile dysfunction]. *Vopr Kurortol Fizioter Lech Fiz Kult* 2020;97:60-67. Russian.
  49. Lurz K, Dreher P, Levy J et al. Low-intensity shockwave therapy in the treatment of erectile dysfunction. *Cureus* 2020;12:e11286.
  50. Inoue S, Hayashi T, Teishima J, Matsubara A. Effect of penile rehabilitation with low intensity extracorporeal shock wave therapy on erectile function recovery following robot-assisted laparoscopic prostatectomy. *Transl Androl Urol* 2020;9:1559-1565.
  51. Kim KS, Jeong HC, Choi SW et al. Electromagnetic low-intensity extracorporeal shock wave therapy in patients with erectile dysfunction: a sham-controlled, double-blind, randomized prospective study. *World J Mens Health* 2020;38:236-242.
  52. Patel P, Katz J, Lokeshwar SD et al. Phase II randomized, clinical trial evaluating 2 schedules of low-intensity shockwave therapy for the treatment of erectile dysfunction. *Sex Med* 2020;8:214-222.
  53. Verze P, Capece M, Creta M et al. Efficacy and safety of low-intensity shockwave therapy plus tadalafil 5 mg once daily in men with type 2 diabetes mellitus and erectile dysfunction: a matched-pair comparison study. *Asian J Androl* 2020;22:379-382.
  54. Wang J, Luo L, Zhao S, Liu Y, Zhu Z, Zhao Z. Low intensity extracorporeal shockwave therapy shifts PDE5i nonresponders to responders. *Int Braz J Urol* 2020;46:934-942.
  55. Wu SS, Ericson KJ, Shoskes DA. Retrospective comparison of focused shockwave therapy and radial wave therapy for men with erectile dysfunction. *Transl Androl Urol* 2020;9:2122-2128.
  56. Zaseda Y. Combined treatment with focused low-intensity shock-wave therapy and androgen-stimulation therapy in men with corporal veno-occlusive erectile dysfunction on the background of hypogonadotropic hypogonadism. *Georgian Med News* 2020;:49-53.
  57. Costa P, Dias J, Gouveia R, et al. Low intensity extracorporeal shockwave therapy on erectile dysfunction—first results from a prospective study. *AME Med J* 2019;4:32.
  58. Musa ZS, El-Assmy A, Shokry AM, Shokeir AA, Zween T, Al-Kenawy MR. Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders. *Arab J Urol* 2019;18:54-58.
  59. Sramkova T, Motil I, Jarkovsky J, Sramkova K. Erectile dysfunction treatment using focused linear low-intensity extracorporeal shockwaves: single-blind, sham-controlled, randomized clinical trial. *Urol Int* 2020;104:417-424.
  60. Vita R, Benvenga S, Giammusso B, La Vignera S. Determinants of early response to low-intensity extracorporeal shockwaves for the treatment of vasculogenic erectile dysfunction: an open-label, prospective study. *J Clin Med* 2019;8:1017.
  61. Wang CJ, Lu YM, Li CC, Wu WJ, Chien TM. Low-intensity shock wave therapy ameliorates erectile dysfunction in men with pelvic fractures associated with urethral injury. *Int J Impot Res* 2019;31:218-222.
  62. Yamaçake KGR, Carneiro F, Cury J, et al. Low-intensity shockwave therapy for erectile dysfunction in kidney transplant recipients. A prospective, randomized, double blinded, sham-controlled study with evaluation by penile Doppler ultrasonography. *Int J Impot Res* 2019;31:195-203.
  63. De Oliveira PS, De Oliveira TR, Nunes Á, Martins F, Lopes T. Low-intensity shock wave therapy for erectile dysfunction and the influence of disease duration. *Arch Ital Urol Androl* 2019;90:276-282.
  64. Fojecki GL, Tiessen S, Osther PJS. Effect of linear low-intensity extracorporeal shockwave therapy for erectile dysfunction-12-month follow-up of a randomized, double-blinded, sham-controlled study. *Sex Med* 2018;6:1-7.
  65. Kalyvianakis D, Memmos E, Mykoniatis I, Kapoteli P, Memmos D, Hatzichristou D. Low-intensity shockwave therapy for erectile dysfunction: a randomized clinical trial comparing 2 treatment protocols and the impact of repeating treatment. *J Sex Med* 2018;15:334-345.
  66. Kitley ND, Vardi Y, Appel B, et al. Low intensity shock wave treatment for erectile dysfunction – how long does the effect last? *J Urol* 2018;200:167-170.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

67. Zewin TS, El-Assmy A, Harraz AM, et al. Efficacy and safety of low-intensity shock wave therapy in penile rehabilitation post nerve-sparing radical cystoprostatectomy: a randomized controlled trial. *Int Urol Nephrol* 2018;50:2007-2014.
68. Ayala HAC, Cuartas JPS, Cleves DC. Impact on the quality of erections after completing a low-intensity extracorporeal shock wave treatment cycle on a group of 710 patients. *Adv Urol* 2017;2017:1843687.
69. Fojecki GL, Tiessen S, Ooster P. Effect of low-energy linear shockwave therapy on erectile dysfunction – a double-blinded, sham-controlled, randomized clinical trial. *J Sex Med* 2017;14:106-112.
70. Kalyvianakis D, Hatzichristou D. Low-intensity shockwave therapy improves hemodynamic parameters in patients with vasculogenic erectile dysfunction: a triplex ultrasonography-based sham-controlled trial. *J Sex Med* 2017;14:891-897.
71. Tsai CC, Wang CJ, Lee YC, et al. Low-intensity extracorporeal shockwave therapy can improve erectile function in patients who failed to respond to phosphodiesterase type 5 inhibitors. *Am J Mens Health* 2017;11:1781-1790.
72. Bechara A, Casabé A, De Bonis W, Ciciclia PG. Twelve-month efficacy and safety of low-intensity shockwave therapy for erectile dysfunction in patients who do not respond to phosphodiesterase type 5 inhibitors. *Sex Med* 2016;4:e225-e232.
73. Frey A, Sønksen J, Fode M. Low-intensity extracorporeal shockwave therapy in the treatment of postprostatectomy erectile dysfunction: a pilot study. *Scand J Urol* 2016;50:123-7.
74. Hisasue S, China T, Horiuchi A, et al. Impact of aging and comorbidity on the efficacy of low-intensity shock wave therapy for erectile dysfunction. *Int J Urol* 2016;23:80-4.
75. Kitrey ND, Gruenwald I, Appel B, Shechter A, Massarwa O, Vardi Y. Penile low intensity shock wave treatment is able to shift pde5i nonresponders to responders: a double-blind, sham controlled study. *J Urol* 2016;195:1550-1555.
76. Bechara A, Casabé A, De Bonis W, Nazar J. [Effectiveness of low-intensity extracorporeal shock wave therapy on patients with Erectile Dysfunction (ED) who have failed to respond to PDE5i therapy. A pilot study]. *Arch Esp Urol* 2015;68:152-60. Spanish.
77. Chung E, Cartmill R. Evaluation of clinical efficacy, safety and patient satisfaction rate after low-intensity extracorporeal shockwave therapy for the treatment of male erectile dysfunction: an Australian first open-label single-arm prospective clinical trial. *BJU Int* 2015;115:46-9.
78. Olsen AB, Persiani M, Boie S, Hanna M, Lund L. Can low-intensity extracorporeal shockwave therapy improve erectile dysfunction? A prospective, randomized, double-blind, placebo-controlled study. *Scand J Urol* 2015;49:329-33.
79. Pelayo-Nieto M, Linden-Castro E, Alias-Melgar A, et al. Linear shock wave therapy in the treatment of erectile dysfunction. *Actas Urol Esp* 2015;39:456-9.
80. Reisman Y, Hind A, Varaneckas A, Motil I. Initial experience with linear focused shockwave treatment for erectile dysfunction: a 6-month follow-up pilot study. *Int J Impot Res* 2015;27:108-12.
81. Ruffo A, Capece M, Prezioso D, et al. Safety and efficacy of low intensity shockwave (LISW) treatment in patients with erectile dysfunction. *Int Braz J Urol* 2015;41:967-74.
82. Srinivasan VS, Reddy RK, Shultz T, Denes B. Low intensity extracorporeal shockwave therapy for erectile dysfunction: a study in an Indian population. *Can J Urol* 2015;22:7614-22.
83. Yee CH, Chan ES, Hou SS, Ng CF. Extracorporeal shockwave therapy in the treatment of erectile dysfunction: a prospective, randomized, double-blinded, placebo controlled study. *Int J Urol* 2014;21:1041-5.
84. Gruenwald I, Appel B, Vardi Y. Low-intensity extracorporeal shock wave therapy--a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. *J Sex Med* 2012;9:259-64.
85. Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. *Int J Androl* 2012;35:190-5.
86. Vardi Y, Appel B, Kilchevsky A, Gruenwald I. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. *J Urol* 2012;187:1769-75.
87. Vardi Y, Appel B, Jacob G, Massarwi O, Gruenwald I. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. *Eur Urol* 2010;58:243-8.